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Abstract: Brd2 belongs to the BET family of epigenetic transcriptional co-regulators that act as
adaptor-scaffolds for the assembly of chromatin-modifying complexes and other factors at target gene
promoters. Brd2 is a protooncogene and candidate gene for juvenile myoclonic epilepsy in humans, a
homeobox gene regulator in Drosophila, and a maternal-zygotic factor and cell death modulator that
is necessary for normal development of the vertebrate central nervous system (CNS). As two copies
of Brd2 exist in zebrafish, we use antisense morpholino knockdown to probe the role of paralog
Brd2b, as a comparative study to Brd2a, the ortholog of human Brd2. A deficiency in either paralog
results in excess cell death and dysmorphology of the CNS, whereas only Brd2b deficiency leads to
loss of circulation and occlusion of the pronephric duct. Co-knockdown of both paralogs suppresses
single morphant defects, while co-injection of morpholinos with paralogous RNA enhances them,
suggesting novel genetic interaction with functional antagonism. Brd2 diversification includes
paralog-specific RNA variants, a distinct localization of maternal factors, and shared and unique
spatiotemporal expression, providing unique insight into the evolution and potential functions of
this gene.

iations.
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1. Introduction
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Brd2 is a member of the bromodomain-extra terminal domain (BET) family of proteins, which act as epigenetic transcriptional co-regulators and are major interpreters of
the acetyl-lysine-histone code [1,2]. BET proteins recognize and bind acetylated histones
via their N-terminal bromodomains and recruit other proteins via their C-terminal ET

conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

J. Dev. Biol. 2021, 9, 46. https://doi.org/10.3390/jdb9040046

https://www.mdpi.com/journal/jdb

J. Dev. Biol. 2021, 9, 46

2 of 36

domains [3]. Thus, they function as adaptor-scaffolds at target gene promoters, providing a surface for the ordered assembly and regulation of various chromatin-modifying
factors and bridging transcription factors at distal elements with the basal transcriptional
machinery [3,4]. Ultimately, BET proteins act to maintain activated or repressed states
of gene expression via signal-dependent modulation of the chromatin structure [5]. Not
surprisingly, BET proteins have been mapped at enhancer sites across the genome [6], are
found at important nodes of interaction within the proteome [7], and are implicated in
multiple biological processes including: meiosis and germline formation [8,9], homeobox
(Hox) gene regulation [10], lineage specification [11,12], hematopoiesis [13], neurogenesis [14], cell cycle progression [15], maintenance of pluripotency [16], and, significantly,
disease states such as cancer [17,18], kidney disease [19], metabolic syndrome [20], and
neuroinflammation [21]. Consequently, small molecule inhibitors of BET proteins (BETi)
have not only revealed BET-regulated transcriptome and proteome changes underlying
different developmental processes, but also, are potential therapeutic agents for multiple
diseases [22]. As master regulators of multiple target genes, BET proteins likely facilitate
crosstalk among different regulatory pathways and biological processes, and act as critical
relay stations for the integration of multiple signals [6,7]. A full understanding of how
these kinds of regulatory networks work, how they grow more complex, and how they
impact evolutionary and developmental trajectories, awaits parallel comparative study of
gene function and interaction in multiple species. The study of BET protein Brd2 across
species in the context of embryonic development illustrates this point.
The role of Brd2 in development has been studied in Drosophila, mouse, and zebrafish, providing a rich source for functional comparison. In each of these species, Brd2
produces both maternal and zygotic gene products necessary for survival and normal embryogenesis, suggesting an ancient, conserved role in germline formation, egg-to-embryo
transition, and/or early embryo developmental events [23–25]. In addition, induced deficiencies of Brd2 during development demonstrate its necessity for the proper patterning,
differentiation and morphogenesis of body segments in invertebrates [4,23,26], and of
segmented tissues, most prominently the central nervous system (CNS), in vertebrates [27].
In Drosophila, ortholog Fsh1 acts as an upstream regulator of various segment-determining
homeobox genes and functions in concert with Trithorax group (Trx-G) proteins, which
form the major activating epigenetic axis in metazoan development [4,23,28]. For instance,
Fsh1 interacts with distal-bound Trx-G chromatin activators at the proximal promoter of
Hox gene Ultrabithorax (Ubx), aiding interaction with the basal transcriptional machinery
and thereby maintaining proper >Hox expression domains in the trunk [4]. A Brd2/Hox
regulatory pathway may in fact be evolutionarily conserved, as a deficiency in the zebrafish
ortholog Brd2a results in misexpression in the developing brain of homeobox gene eng2a and
paired box gene pax2a, both of which are known targets of Fsh1 in Drosophila [27]. Brd2a
deficiency in zebrafish embryos also results in the mispairing of hindbrain (HB) and ventral
nerve cord (VNC)-derived spinal interneurons on either side of the midline, suggesting
that Hox-dependent patterning of the CNS in this region is defective [27]. In addition,
Brd2 is necessary for Hox-dependent patterning and differentiation in hematopoietic tissue
in zebrafish and mice [29,30]; whether Brd2 affects the formation of other non-neuronal
Hox-dependent tissues needs further investigation.
In contrast to these conserved roles, the regulation of neuronal apoptosis appears to be
a recently derived and specifically vertebrate developmental function of Brd2, as deficiency
results in dramatic increases in cell death in the embryonic CNS of mice and zebrafish,
but not flies [27,31,32]. Brd2 knockout mice display excess apoptosis, impaired growth,
and brain and neural tube defects [31], and, in other studies, exencephaly and significant
changes in the expression of neurogenesis genes [32]. In zebrafish embryos, sublethal
knockdown of Brd2a results in excess apoptosis during segmentation, when the CNS is
undergoing differentiation and morphogenesis, leading to reduced hindbrain, undefined
midbrain-hindbrain boundary region, and deformed spinal cord [27]. Surprisingly, the
deficiency of Brd2 has little overall effect on mitosis in mouse or fish embryos [27,31,32],
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despite the fact that it is a known protooncogene and facilitator of the E2F-dependent
transactivation of cell cycle genes in adult mammalian tissues [33]. Indeed, mammalian
Brd2 was known early on to be upregulated in some forms of human B cell lymphomas and
leukemias; subsequently, its forced overexpression in the lymphoid compartment in transgenic mice was shown to lead to these same blood cancers [34]. The pro-mitotic function of
Brd2 might thus be prominent in adult tissues, but play a more restricted specialized role in
embryogenesis. Since Brd2 shuttles into the nucleus of mouse neuronal precursors during
both mitotic and apoptotic events in normal development [35] and is necessary for the cell
cycle exit and differentiation of mouse neuroepithelial cells in vivo [36], it likely plays a
role in cell fate decisions between division, differentiation, and death, at least in neuronal
populations. In any case, Brd2 appears to be a dual regulator of both apoptosis and mitosis
in vertebrates, depending on the context. Brd2 is also implicated in human disease states
that are relevant to its role in neuronal development, including neurodegeneration following stroke [37], and the defective neurogenesis underlying juvenile myoclonic epilepsy
(JME) [38].
Because the zebrafish genome contains two copies of the Brd2 sequence [25], comparative studies of the resultant paralogs can provide a unique window into the developmental
functions, interactions, and recent evolution of this important gene. As summarized above,
we previously described the developmental role of the Brd2 ortholog in zebrafish, brd2a [27].
We also showed that both zebrafish paralogs, brd2a and brd2b, encode maternal and zygotic products, and are expressed in largely (but not exclusively) overlapping domains
in the embryo, becoming enriched in the developing central nervous system and ventral
trunk during segmentation stages [25]. On the other hand, they differ strikingly in the
localization of maternal RNAs in the oocyte, in the RNA variants expressed in the embryo,
and in genomic sequence and structure [25]. In particular, paralog brd2b produces a short
RNA splice variant that potentially encodes a truncated protein carrying only bromodomain 1 (BD1). This suggests a dominant negative function for this isoform, leading us
to wonder whether the two paralogs might be functional antagonists [25]. The work of
others identifying brd2b as a tumor suppressor gene in zebrafish—opposite to the known
protooncogene function of the human ortholog of brd2a [39]—supports this idea. In this
study, we examine the developmental function of zebrafish paralog brd2b using antisense
morpholino knockdown, and compare the findings to what we already know about the
developmental role of brd2a, the ortholog of human Brd2. We uncover novel functions for
Brd2b in the formation of the circulatory and excretory systems, and most significantly,
demonstrate the occurrence of genetic interaction with functional antagonism between
the two zebrafish paralogs during development. Our study is likely to inform a deeper
understanding of Brd2 activity in mammals, and it also provides a concrete example of
recent gene duplication and divergence in vertebrates, illustrating possible mechanisms
of paralog diversification and interaction that may underlie the complexification of gene
regulatory networks during development over evolutionary time.
2. Materials and Methods
2.1. Fish Maintenance and Handling
Adult wildtype zebrafish (Danio rerio, strain AB, University of Oregon, Eugene OR)
were maintained at 28.5 ◦ C on a 14 h light:10 h dark cycle and fed twice daily with a
mixture of live brine shrimp and Zeigler Adult Zebrafish food (Pentair-AES, Cary, NC,
USA). Embryos were generated from natural crosses in mating boxes, kept in E3 medium at
28.5 ◦ C before and after microinjection, and staged by standard morphological criteria [40].
All experiments were conducted in accordance with protocols approved by the University
Committee on the Use and Care of Animals (IACUC), Villanova University.
2.2. RNA Isolation and RT-PCR
For RNA isolation, ovaries were dissected and treated with Follicle Dissociation buffer
(FDB; 400 µg/mL collagenase in Hank’s) for 10 min. After washing in Hank’s, ovaries were
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placed in ice-cold PBS for oocyte separation by stage. Embryos were dechorionated in E3
medium, incubated at 28.5 ◦ C, and collected at selected stages using characteristic features
according to Kimmel et al. [40]. RNA from oocytes and embryos was isolated using TRIzol
reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to company protocol.
Briefly, 25 oocytes or 50 embryos per stage were homogenized in 1 mL of TRIzol in a 1.5 mL
microfuge tube using a motorized pestle, with subsequent addition of 200 µL chloroform.
Samples were gently mixed, incubated at room temperature for 2 min, and centrifuged
at 12,000× g for 15 min at 4 ◦ C. The aqueous layer was transferred to a fresh tube with
500 µL of isopropanol, incubated at room temperature for 10 min, and then centrifuged as
before. The pellets were washed in 1 mL of 75% ethanol, centrifuged at 7500× g for 5 min
at 4 ◦ C, air dried for 10 min, and resuspended in 100 µL of RNase-free water. RNA samples
were then purified using the Qiagen (Germantown, MD, USA) RNeasy kit with on-column
DNase treatment, according to company protocol. The final RNA samples were quantified
using a Nanodrop spectrophotometer prior to cDNA synthesis.
The cDNA template for RTqPCR was synthesized using the iScript cDNA synthesis
kit (Bio-Rad), according to company protocol. Briefly, for each sample, 1.5 µL of RNA
(typically 0.75 µg) was added to 13.5 µL iScript RNase-free water and 4 µL iScript reaction
mix, heated to 65 ◦ C for 2 min, then supplemented by 1 µL iScript reverse transcriptase and
incubated in a Bio-Rad thermal cycler with heated lid as follows: 42◦ C for 60 min, 85 ◦ C
for 5 min, and 4 ◦ C hold. A quantity of 20 µL of nuclease-free water was added to each
sample and aliquots were stored at −20 ◦ C until use.
To assay for brd2b-L and brd2b-S mRNAs in vivo, exon–exon junction-spanning primers
were designed for exon pairs 5/6 (forward 50 -CCAGATTCGCAGTTCTCCAC; reverse
50 -CTCTTCGGGAGGGCTGAT), 9/10 (forward 5-GGGACAAACCTGCCAAACT; reverse
50 -GCAGTGAAGGCTCTCTGGAC) and 11/12 (forward 50 -GTCGAGAGGAGTTGGCTCTG;
reverse 50 -GATTCCACGGTTTCCCATTA) of the predicted full-length transcript (Ensembl_Trans:
ENSDART00000148709, brd2b-202), and the exon5/intron5 junction (forward 50 -CACGCGC
ACACACTTTTTAT reverse 50 -TTTAGTTTGCAGGGCGAGAG) of the shorter truncated
transcript (NM_001110524.1). RTqPCR was performed on cDNA from the RNA of staged
oocytes (stages I–IV) and embryos (4, 24, 48 hpf). Primers for positive control β-actin (forward
50 -GCAGAAGGAGATCACATCCCTGGC; reverse 50 -CATTGCCGTCACCTTCACCGTTC)
and for negative genomic control intron 1 (forward 50 -CAGTGTCTGTTTTTGGCTCGG;
reverse 50 -GGTCTCATTTTCCCCCAAAAGC) were also used in each experiment. RTqPCR
was performed using Qiagen SYBER Green Real-Time PCR master mix. For each sample
and each primer pair, 3 µL of five-fold diluted aliquots of cDNA were mixed with 10 µL of
Evergreen master mix, 0.2 µL of 100 µM forward primer, 0.2 µL of 100 µM reverse primer,
and 6.6 µL of nuclease-free water, in a well of a 96-well dish. Samples were placed in a
real-time PCR detection system (CFX Connect Bio-Rad, Hercules, CA, USA) for 39 cycles
of the following protocol: 95 ◦ C, 5 min; 95 ◦ C, 30 s; 58 ◦ C, 30 s; and 78 ◦ C, 3 min. The
expected size and sequence of PCR products was confirmed by gel electrophoresis and
cycle sequencing, respectively.
2.3. Brd2b Peptide Antibody Production, Western Blot and Peptide Competition
Anti-Brd2b peptide polyclonal antibody was generated in rabbits by Genescript (Piscataway, NJ, USA) against the antigenic determinant KSSRASLSSSQSKK, which was
assessed by Blastp to be unique to Brd2b in the zebrafish proteome and is not present in the
paralog (Brd2a) or other BET family members. Protein bands detected by the anti-Brd2b
peptide antibody are erased by peptide competition, indicating specificity of the antibody
for the antigenic determinant, and presence of the peptide sequence in all detected proteins
(see below). As the peptide epitope resides just before the ET domain, only the full-length
isoform Brd2b-L, and not Brd2b-S, can be detected by this peptide antibody.
For western blot analysis, oocytes and embryos were collected as described above
for RTqPCR, and samples were homogenized in 1.5 mL microfuge tubes in 45 µL of
RIPA buffer (50 mM Tris-Cl pH 8, 150 mM NaCl, 0.5% sodium deoxycholate, 1% NP40,
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0.1% SDS) with added Roche mini protease inhibitor cocktail (Millipore-Sigma, Burlington,
MA, USA) and rotated at 4 ◦ C for two hours. After centrifugation at 12,000 rpm for
15 min to pellet debris, supernatants were transferred to fresh tubes, 45 µL of 2× SDS
loading buffer was added, and tubes were vortexed and placed at 100 ◦ C for 5 min,
before sample loading on 8% polyacrylamide gels (Thermo Fisher Scientific, Waltham,
MA, USA) and electrophoresis at 100 V for 50 min. Transfer to nitrocellulose membranes
was conducted at 40 V for 90 min at room temperature in a Bio-Rad mini-Protean transfer
unit with an ice pack. To assess equal loading across lanes, all membranes were stained
after transferring with the Memcode Reversible Protein Stain (Thermo Pierce, Waltham,
MA, USA) and imaged to visualize total protein before antibody incubations, as per
company protocol. This process was undertaken in lieu of reprobing blots with antibodies
to a control “housekeeping” protein, as this was found to be problematic in terms of
efficiency of binding in reprobed membranes. Membranes were rinsed in PBST, blocked
in PBST/5% dry milk at room temperature for 2 h, then placed in 6 mL PBST/1% dry
milk containing 12 µL anti-Brd2b primary antibody (1/500 dilution) and incubated at
4◦ C on shaker overnight. After washing in PBST, membranes were incubated in 10 mL
PBST/1% dry milk with 3 µL of goat anti-rabbit-HRP secondary antibody (Pierce) at room
temperature for 2 h, with shaking. After PBST washes, membranes were incubated in
Supersignal West Dura detection buffer (Thermo-Fisher Scientific, Waltham, MA, USA)
for 5 min and imaged by means of chemiluminescence. Precision Plus Protein dual color
and WesternC molecular weight markers (Bio-Rad, Hercules, CA, USA) were used as size
standards.
For peptide competition, duplicate blots of identical samples were prepared, and
prestaining with Memcode was conducted as above. One blot was incubated with antiBrd2b primary antibody; the second blot was incubated with anti-Brd2b primary antibody
that had been first pre-incubated with 15 µM of reconstituted peptide (Genescript, Piscataway, NJ, USA) in PBS for 2 h at room temperature. Secondary antibody treatment
and detection was conducted as above for both membranes. Brd2b protein expression
differences between the MO-treated and control embryos were estimated by measuring
band pixel densities for each sample lane on blots using ImageJ FIJI, and then standardizing
to total protein loaded for that lane. Total protein loaded per sample was estimated by
measuring and summing pixel densities for the visible Memcode bands per lane/sample.
2.4. Full-Length cDNA Cloning
A cDNA clone of brd2a was previously obtained in a screen of a cDNA library from 15 to
18 hpf zebrafish embryos and was subcloned directly into the pCS2+ vector. cDNA sequences
for brd2b-L and brd2b-S were obtained by RTqPCR from embryonic RNA using primers from
the brd2b predicted sequences in the ZFIN database (Ensembl_Trans:ENSDART00000148709,
brd2b-202). Primers for brd2b-L: forward 50 -AGGTGCAGAATAGCAATAAAACG; reverse 50 GCAGTTCCTAAACTCTCATTACCTTC. Primers for brd2b-S: forward 50 -GGTGAGCTCGA
GCATAAGGT; reverse 50 -TGCCAATTTAGTTTCAATAGTTCA. PCR products were first
cloned into pCR 2.1 TOPO vector and inserts representing both brd2b short and long
cDNAs were confirmed by sequencing. Both long and short brd2b cDNAs were then
subcloned into pCS2+ vector by PCR using primers designed to exclude the brd2bMO2
binding site. The pCS2+ vector contains transcriptional start and stop sequences, and
a poly-adenylation signal, and allows for in vitro transcription of sense RNA for use in
rescue-enhancement studies described below.
2.5. Antisense Morpholino Treatments
Gene-specific antisense morpholino oligonucleotides (MOs) were purchased from
GeneTools, LLC (Philomath, OR, USA). Stock MO solutions (1 mM) in sterile glass distilled water were diluted to various working concentrations in 1× Danieau buffer and
0.15% phenol red, and a constant volume of 2 nL MO working solution was injected
into each 1–4 cell stage embryo using a Leitz micromanipulator (Leica Microsystems,
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Inc., Wetzlar, DEU) and a PV820 pneumatic picopump (World Precision Instruments,
Sarasota, FL, USA)). Two independent brd2b-specific MOs targeting non-overlapping regions of the 50 UTR and/or region surrounding the initiation codon of zebrafish brd2b
were designed with company help: 2bMO1 (50 -CTTTGCGGTGCGAAATCCTGCGTTT-30 ),
targeting 25 bases of 50 UTR 18 bases upstream of the putative start codon; and 2bMO2
(50 -ATTGCTATTCTGCACCTTCTGCTCG-30 ), targeting 25 bases of 50 UTR upstream of
MO1. The uniqueness of each MO target was verified by Blastn searches of the zebrafish
transcript and genomic databases at NCBI. A standard negative control MOc supplied by
the company (50 -GGTTTCGCTCGAATATCCGAGTTTC-30 ), and a five base-pair mismatch
to 2bMO1 (2bMO1mis5; 50 -CTTTcCGcTGCcAAATaCTGCcTTT-30 ) were used to test for
general non-specific toxic effects and effective range dosage, respectively. Morpholinos
against brd2a were previously described and authenticated [27].
To determine the effective range of morpholino dosage, working 2bMO solutions
between 0.5 and 8 ng/nL were tested on a total of 25–40 embryos per treatment for brain
defects at prim 5. An MO concentration was deemed to be in the effective range if it caused
characteristic and easily identifiable defects in brd2b morphants compared to wildtype,
while the standard control morpholino (MOc) and five-base mismatch (2bMO1mis5) at the
same concentration caused no effect. Using these criteria, injected brd2bMO1 amounts from
1 to 6 ng were judged to be within the effective range; brd2bMO2 was then tested in this
same range. The incidence of brain defects varied significantly both by treatment within
each dosage in the effective range (p < 0.0001, chi square contingency and Fisher’s exact
test), and by dosage (p < 0.0001, Cochran–Mantel–Haenszel test). Differences between
uninjected “none” and “MOmis5” treatments were not statistically significant, either within
each dosage or across dosages, while differences between “2bMO1” and either “none” or
“MOmis5” were significant (Correspondence analysis). For experiments in this paper, 2 ng
2bMO total amounts were used, unless indicated otherwise.
For initial RNA rescue experiments, sense mRNA lacking brd2bMO binding sites
was synthesized from linearized pcDNA1-Amp vector carrying HA-tagged human Brd2
(NM_005104.4) using the mMESSAGE mMACHINE T7 Capped RNA transcription kit
(Ambion Inc., Austin, TX, USA). Synthesized mRNA was sized and quantified by standard
formaldehyde gel electrophoresis. Embryos were co-injected with 2 ng of either brd2bMO1
or brd2bMO2, and different amounts of sense RNA ranging from 50 to 500 pg, before selecting 250 pg as the standard for co-injections. For co-injections with antisense p53 morpholinos (p53MO, GeneTools, Philomath, OR, USA), each morpholino alone (2–4 ng brd2bMO1;
4 ng p53MO), and the combination (4:4 ng brd2bMO1:p53MO; or 2:4 ng brd2bMO1:p53MO)
was injected. For co-knockdown of Brd2b and Brd2a, a mix of brd2aMO (4 ng) and brd2bMO
(2 ng) morpholinos was injected. We detected no sequence complementarity between any
of the brd2a and brd2b morpholinos we used, and we obtained the same suppressor effects;
however, we mixed MO1 or MO2 morpholinos from each locus. In addition, we conducted
sequential (rather than mixed) injections in subsequent experiments and obtained the same
co-knockdown effects.
For rescue-enhancement studies, sense RNA was synthesized from cloned zebrafish
brd2a, brd2b-L and brd2b-S cDNAs (see full-length cDNA cloning above) using the mMESSAGE mMACHINE Sp6 Capped RNA transcription kit (Ambion Inc., Austin, TX, USA).
Working solutions were made by diluting RNA to 100ng/µL using in 0.1 M KCl, embryotested water (Millipore-Sigma), and 0.1% phenol red. A quantity of 2 nL of working
solution was microinjected into embryos at the 1–4 cell stage for all rescue and enhancement studies, since at this dosage all three synthetic RNAs injected on their own produced
a mild phenocopy of the morphant phenotype but did not result in uncharacteristic or
severe defects. For rescue studies, morpholinos were injected in 4 ng amounts, while for
enhancement studies, morpholinos were injected in amounts of between 2 and 4 ng to
allow for enhancement to be detected more easily.
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2.6. Crispr-Cas9 Disruption
Clustered regularly interspaced short palindromic repeats (CRISPR) crRNA was
designed against the brd2b gene on chromosome 16 using CRISPRscan (http://www.
crisprscan.org, accessed on 16 June 2016 and purchased along with tracerRNA (trRNA) and
Cas9-mRNA from GE Health Dharmacon Inc. (Lafayette, CO, USA) The following brd2b
RNA coding sequence was targeted from NM_001110524.1, Exon 2: GUGGCUCGUCCUUGUCGGCUGUUUUAGAGCUAUGCUGUUUUG. Stock solutions of crRNA (1 ng/µL
in TrisCl pH 7.4 RNase free) were added at equal concentrations to trRNA and incubated on ice with 2X concentration of Cas9-mRNA for 5 min. The CRISPR solution
(crRNA + trRNA + Cas9-mRNA) was then injected into the animal pole of 1 cell stage
embryos using a Leitz micromanipulator (Leica Microsystems, Inc. Wetzlar, DEU) and a
PV280 pneumatic picopump (World Precision Instruments). The efficiency and specificity
of brd2b crRNA was assessed by PCR cloning followed by mismatch detection using T7
endonuclease I assay (Guide-It Mutation Detection kit, Takara Bio/ClonTech, Mountain
View CA, USA). Briefly, five uninjected and five Crispr-injected embryos at prim 5 stage
were incubated in 100 µL of 50 mM NaOH for 10 min at 95 ◦ C, then cooled to 4 ◦ C and
neutralized with 1/10 volume of 1 M Tris-Cl, pH 8.0. Debris was removed was removed
by centrifugation and 5 µL of supernatant was used in PCR, according to kit instructions. Primers for amplification of the targeted brd2b region were selected using Primer
3: forward 50 -CGAGTTCCGTTCATACCAATC and reverse 50 -TCGAAACTGTGTCAATCCAGA. PCR products were denatured and allowed to anneal slowly before digestion with
the Resolvase enzyme from the kit and gel electrophoretic analysis. Crispr-Cas9 efficacy
was estimated using ImageJ FIJI by comparing pixel density of intact PCR product bands
from Crispr-disrupted thouembryos, with and wit resolvase treatment. Typically, a total
of 20–30 embryos (F0) was used per treatment group in each experiment and were scored
for morphological brain defects characteristic of brd2b morphants, as well as assayed by
Terminal Transferase dUTP Nick End Labeling (TUNEL) for cell death levels.
2.7. In Situ Hybridization
In situ hybridizations to RNA in whole mount zebrafish embryos were conducted
according to the Schulte–Merker protocol as found in the Zebrafish Book [41], with slight
modification. Acetic anhydride and proteinase K treatment were used on older embryos
only (>18 hpf). Digoxigenin (DIG) labeled RNA probes were prepared according to company instructions (Roche Biochemicals, Basel, CHE), and were used directly in hybridizations without prior hydrolysis. Hybridizations were conducted with 1 ng/mL probe in
50% formamide buffer with 5 mg/mL torula yeast, type VI (Sigma, St. Louis, MO, USA),
and without heparin, at 65 ◦ C overnight. Post-hybridization washes (50% formamide,
2× SSCT; 2× SSCT; 0.2× SSCT) were carried out at 55 ◦ C, without RNase treatment. The
embryos were blocked in PBST plus 10% FBS, 0.1% Tween-20, and 1% DMSO for 4 h before
anti-DIG detection in staining buffer plus 1 mM levamisol. After detection, the embryos
were fixed overnight in 4% paraformaldehyde, then dehydrated and stored in methanol at
−20 ◦ C. For imaging, embryos were cleared in 2 parts benzylbenzoate: 1 part benzylalcohol
and mounted in Canada balsam. For In situ examination of ovaries, the high-resolution
whole-mount protocol of Thisse, as described in The Zebrafish Book [41], was followed
exactly. Images of 5–7 representative embryos were taken on a dissecting scope fitted with
a Leica DC camera (Leica Microsystems, Wetzlar, DEU)).
2.8. Immunohistochemistry
For immunohistochemistry, staged embryos or dissected ovaries were fixed in 4%
paraformaldehyde in PBS overnight at 4 ◦ C, then washed in PBS, permeabilized in an
ascending methanol/PBS series and stored in 100% methanol at −20 ◦ C. Embryos that
were 24 hpf or older were dechorionated before, and younger embryos after, fixation. For
the Pax2a experiments, samples were rehydrated in a descending methanol/PBS series,
treated with 24 µg/mL proteinase K/PBS for 5 min, washed again in PBS, incubated for one
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hour at room temperature in block solution (5% normal goat serum, 3% TritonX, 1× PBS),
and then incubated in a 1: 200 dilution of rabbit anti-Pax2a primary antibodies (GeneTex,
Irvine, CA, USA) in blocking solution overnight at 4 ◦ C. After washing in PBS, samples
were incubated in goat anti-rabbit Alexa555 secondary antibodies (Vector Laboratories,
Burlingame, CA, USA) in PBS for one hour at room temperature, and washed again in
PBS. Embryos were mounted on glass slides with Vectashield with DAPI stain (Vector
Laboratories, Burlingame, CA, USA) and imaged by conventional fluorescence (Leica DM
LMD), or laser-scanning confocal (Leica TCS SP8) microscopy, and optical sections and
3D maximum projection images were obtained. Pax2a(+) cells in the pronephros were
counted by manual tagging of lif files using ImageJ (FIJI) software. Pax2a(+) interneurons
were analyzed for pairing on either side of the central verve cord by counting the number
of symmetrically opposed interneuron pairs and the number of interneurons appearing
solo on either one or the other side of the nerve cord, and comparing these numbers
in uninjected control and morpholino-injected embryos. Three-dimensional maximum
projection confocal images of the dorsal spinal cord from 3 to 6 samples per treatment
group were analyzed by ImageJ FIJI software and chi-square contingency tests.
2.9. TUNEL Analysis
Embryos were fixed overnight in 4% PF/1% DMSO/PBS at 4 ◦ C, dehydrated through
an ascending methanol/PBS series, and stored in methanol at −20 ◦ C overnight. After
rehydration, embryos were treated as per the ApopTag Fluorescein In Situ Apoptosis
Detection Kit protocol (Millipore-Sigma, Burlington, MA, USA). Blocking was conducted
for one hour in fetal bovine serum (FBS)/PBST, and embryos were incubated overnight with
100 µL working strength anti-digoxigenin-fluorescein conjugate at 4 ◦ C in dark. Embryos
were mounted in Vectashield on glass slides with footed coverslips for fluorescence imaging.
Fluorescent TUNEL was visualized with a TCS SP8 laser-scanning confocal microscope
(Leica Microsystems, Inc., Wetzlar, DEU), and 55–60 optical sections and 3D maximum
projection images were quantitatively analyzed. Alternatively, a conventional DM LMD
fluorescence microscope (Leica Microsystems, Inc., Wetzlar, DEU) was used, and 15 to
35 optical sections (depending on experiment) were analyzed. Cell counts were obtained
by manual tagging of lif files using ImageJ (FIJI) software. Cell death counts from three
to seven embryos per treatment, depending on experiment, were analyzed for statistical
significance by one way ANOVA, ANOM (Analysis of Means) and Tukey’s HSD tests,
using JMP Pro13 software.
2.10. Phenotypic Assessment and Population Data
Phenotypic assessments were carried out at a population level to assess expressivity
and penetrance. Typically, a total of between 30 and 60 embryos were used per treatment
group in each morpholino experiment (MO knockdown, RNA rescue, p53MO co-injection,
suppression-enhancement studies) unless noted otherwise, and were scored for morphological brain and trunk defects. Brain defects were also rated mild, moderate, and severe
in some experiments to assess expressivity. Phenotypic population data were analyzed
for significant differences between treatments by chi square contingency, Fisher’s exact
tests and Correspondence analysis. For TUNEL, In situ hybridization (ISH), and the immunohistochemical (IHC) assays, a total of 20–50 embryos per treatment, depending on
experiment, were first examined qualitatively for characteristic morphological defects, then
3–10 representative embryos were selected for imaging and quantitative analysis by one
way ANOVA, ANOM, and Tukey’s HSD tests, using JMP Pro13 software.
3. Results
3.1. Zebrafish brd2b Exhibits Transcript Variants Differentially Regulated during Development
We originally cloned zebrafish brd2a and brd2b coding sequences from a cDNA library
made from 15 to 19 h post fertilization (hpf) embryos, using a degenerate probe derived
from the conserved first bromodomain of mammalian Brd2 [25]. The zebrafish brd2a
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cDNA encoded a canonical full-length BET protein (3.9 kb, 836 aa; NP_001257500.1),
orthologous to human Brd2, containing two N-terminal bromodomains (BD1, BD2), a
nuclear localization signal (NLS), and a C-terminal extraterminal (ET) protein-interaction
domain [1]. The brd2b cDNA, however, appeared to be a truncated sequence (1.4 kb) from
a paralogous locus, derived from an alternatively spliced mRNA that retained intronic
sequences at the exon5/intron5 splice junction and terminated within that intron (Figure 1B,
brd2b-S; NM_001110524.1) [25]. The retained intron introduced a premature stop codon
to the protein coding sequence. Thus, when conceptually translated, this short transcript
variant (brd2b-S) would produce a truncated Brd2b protein (Brd2b-S) of 276 amino acids,
having only a single bromodomain 1 (BD1), and lacking the second bromodomain (BD2),
NLS, and ET domain characteristic of BET proteins (NP_001103994.1). As a full-length
Brd2b protein (Brd2b-L in this paper) is predicted algorithmically (Figure 1A, Brd2b-L,
811 aa; Figure 1B, brd2b-L, 4037 nt; transcript—Ensembl_Trans:ENSDART00000148709,
brd2b-202, Ensemble release GRCz11), the existence of a truncated version (Brd2b-S)
suggested to us a possible dominant negative function, whereby it might compete with
Brd2b-L and/or its paralog Brd2a for chromatin target sites, while being itself “cargo-less”
due to the lack of the protein interaction ET domain. To verify that brd2b-S was an actual
in vivo transcript rather than a cDNA library cloning artifact, and to empirically confirm
the presence of predicted exons of the longer transcript (brd2b-L), as found in the present
databases, we designed primer pairs spanning diagnostic exon–exon junctions in the two
cDNAs, and conducted RT-PCR on RNA isolated from stage I–IV oocytes and from 4, 24,
and 48 h post fertilization (hpf) embryos (Figure 1B, exon 5/6, exon 9/10, exon 11/12
primers from brd2b-L, and exon5/intron5 primers from brd2b-S; Figure 1C, key of primer
pairs and their predicted products; gels showing RT-PCR products obtained). brd2b-L exons
are present in all tested oocyte stages and embryos (Figure 1C, blue arrowheads, lanes
labeled 3, 4, and 5, all sample gels). We also observed PCR product from exon5/intron5
primers diagnostic for the alternative brd2b-S transcript, which we verified by sequencing.
Strikingly, in contrast to the full-length RNA, brd2b-S predicted products are detected
unquestionably only in later stage embryos (Figure 1C, red asterisks, lane labeled 2, for
24 and 48 hpf sample gels only). The faint bands visible in lanes labeled 2 for stage
1,2,3 oocyte samples are either smaller than the predicted brd2b-S product (s1, s2 gels) or
among multiple very faint bands in a lane (s3 gel), leading us to consider them spurious.
Nevertheless, we cannot rule out completely the possibility that the very faint band near the
correct size (s3 gel) might represent brd2b-S at very low levels, although we consider this
unlikely. Importantly, primers derived exclusively from within intron 1 show no product
(Figure 1C, lane labeled 9 for each sample gel), ruling out genomic DNA contamination as
a source template. These data corroborate our previous analyses by Northern blot, where
we detected brd2b RNA variants of corresponding sizes, with longer RNAs (4 and 6 kb)
observed in ovaries and embryos of all stages, and a short mRNA of about 1.8 kb only
in embryos starting between 8 and 10 hpf and persisting through 48 hpf [25]. Thus, both
brd2b-L and brd2b-S transcript variants are detected in vivo, and show distinct tissue and
temporal patterns of expression.
3.2. brd2b Encodes a Maternal/Zygotic Factor That Is Localized to the Animal Pole in Oocytes and
Enriched in the CNS and Ventral Trunk in Embryos
To study the protein products of the brd2b locus, we generated antibodies against
zebrafish Brd2b using synthetic peptides derived from the predicted amino acid sequence
and verified by Blastp to be unique in the zebrafish genome. The first peptide epitope
we targeted resides between the NLS and the ET domain, so derived antibodies would
detect the predicted Brd2b-L protein isoform but not putative Brd2b-S. Using this antibody
in western blot analyses, we found a major band of >150 kD consistently detected in
ovaries/oocytes and in 48 hpf embryos, but inconsistently and at very low levels at 24 or
4 hpf (Figure 2A). Another major band between 50 and 75 kD is consistently detected in
embryos at 48 hpf, less prominently at 24 hpf, sometimes faintly at 4 hpf, and rarely in
ovaries/oocytes (Figure 2A; Supplementary Figure S1). All bands are subtracted by peptide
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competition (Figure 2, compare A with C), indicating detected proteins contain the peptide
epitope and are likely Brd2b isoforms or breakdown products. Prestaining of blots for total
protein (Figure 2B,D) shows that lack of signal on blot in C is due to peptide competition
during antibody incubation and not due to lack of protein loading. It is possible that the
band at >150 kD represents full-length Brd2b-L (predicted MW 91 kD), where differences
from the predicted might be due to post-translational modification and/or stable complex
formation [42]. In any case, the putative full-length protein is found in both ovaries/oocytes
and embryos, while the smaller product is most prominently found in later stage embryos.
In addition, the presence of both the brd2b-L mRNA and the putative Brd2b-L protein in
both ovaries/oocytes and embryos supports the correspondence of this pair as maternal
(and zygotic) products. We attempted to detect the putative short isoform Brd2b-S, using
antibodies against an N-terminal epitope upstream of BD1 that was common to Brd2bL and Brd2b-S, but this antibody was ineffective and unable to detect either isoform in
any sample.
3.3. Brd2b Knockdown Results in Reduced Hindbrain, Ill-Defined MHB, and Trunk Abnormalities
Similar to Brd2a Morphants, but Presents Unique Circulatory and Pronephric Defects
We showed previously that a deficiency of Brd2a during zebrafish development results
in malformation of the neural tube, somites, and post-anal trunk, reduced hindbrain and
ill-defined midbrain-hindbrain boundary (MHB), mispairing of spinal interneurons, and
abnormal numbers of Pax2a(+) cells in ventral trunk—all accompanied by a dramatic
misregulation of cell death and of some of the genes necessary for proper formation of the
MHB and anterior hindbrain [27]. Here, we conduct a comparative study to examine the
effects of the deficiency of paralog Brd2b, using both antisense morpholinos and CrisprCas9 disruption. We designed two independent non-overlapping antisense translational
block morpholinos (brd2bMO1 and brd2bMO2) to assess morphant phenotypes and used
two control morpholinos (MOc and MOmis5) to control for general toxicity and determine
effective dosage range for subsequent studies (see Materials and Methods).
We first surveyed visible phenotypes of Brd2b morphants at various stages of development after injection of 2–4 cell embryos with 2 ng of brd2bMO, typically examining a total
of 40–60 embryos from three independent clutches per treatment. We injected 2 ng MO
as it was the lowest dose in the effective range (1–6 ng) that consistently produced clear,
mostly penetrant morphant phenotypes (see Materials and Methods). brd2bMO morphants
begin to show defects in early segmentation stages, and by prim 5 characteristic head
abnormalities are clearly seen, including reduced overall brain size, collapsed hindbrain
ventricle, and reduced and/or ill-defined MHB region (Figure 3A vs. Figure 3B,D). Both
brd2bMO1- and brd2bMO2-injected morphants give the same characteristic brain abnormalities (Figure 3B,D), as do embryos treated with Crispr-Cas9 to disrupt the brd2b gene
(Figure 3E). Population data show statistically significant differences between control and
experimental treatment groups for these studies (Table 1, brd2bMO single knockdown, p <
0.0001). Importantly, we obtained substantial rescue of brd2bMO morphant brain defects by
co-injection with in vitro-synthesized human Brd2 mRNA (HsBrd2RNA) lacking brd2bMO
target sequences (Figure 3C; Table 1, brd2bMO1+/−HsBrd2RNA rescue, p < 0.0001). These
brd2bMO morphant brain defects recapitulate what we found previously with knockdown
of Brd2a (Figure 3F), except that they are typically more highly penetrant, and manifest
reliably at lower MO doses (2 ng brd2bMO vs. 4 ng brd2aMO).
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Figure 1. brd2b transcript variants are differentially regulated during development. (A) Schematic of
predicted proteins from the brd2b locus, full-length Brd2b-L and truncated Brd2b-S. Bromodomains BD1
and BD2 (ovals), nuclear localization signal (NLS, triangle), and a C-terminal extraterminal (ET) domain
(rectangle). (B) Schematic of the long (brd2b-L) and short (brd2b-S) transcript variants encoded by the brd2b
locus, with numbered exons. UTRs of 50 and 30 are shown in white; protein-coding regions are shown in
orange. The short transcript retains part of intron 5 (shown in yellow), which introduces a premature stop
codon (darker yellow shows part of intron that is translated). Primer pairs flanking exon–exon junctions
and used in RT-PCR are shown as dark blue arrows. (C) RT-PCR products produced from mRNA of
staged oocytes (top gels) and 4, 24, and 48 hpf embryos (bottom gels), using various primer pairs, as
shown in B. Lanes labeled with the same number display the PCR product obtained using the same primer
pairs, as shown in the key: (1) 1 kb ladder (NEB); (2) ex5/in5 primers (brd2b-S 250 bp predicted product);
(3) ex5/6 primers (brd2b-L 400 bp predicted product); (4) ex9/10 primers (brd2b-L 300 bp predicted product);
(5) ex11/12 (brd2b-L 404 bp predicted product); (6) ex1/in5 primers (full-length brd2b-S 1447 bp predicted
product); (7) ex1/ex12 primers (full-length brd2b-L 4037 bp predicted product); (8) primers for β-actin (+)
control (322 bp predicted product); (9) primers internal to intron 1 (not shown in B), as (−) control for
genomic DNA (784 bp predicted product). Maternal brd2b-L predicted PCR products are detected in all
stages of ooctye tested (blue arrowheads, lanes labeled 3,4,5, top gels), but brd2b-S predicted products are not
present (lanes labeled 2, top gels). The bands observed in stage 1, 2 and 3 oocytes in lanes labeled 2 are either
smaller than the 250 bp predicted product for brd2b-S (s1, s2 gels), or are very faint products among several
faint products (s3 gel), so are likely a spurious. Zygotic brd2b-S predicted product is detected in 24 hpf and
48 hpf embryos (red asterisk, lanes labeled 2, bottom gels), but not in 4 hpf embryos, while zygotic brd2b-L is
detected in all stages of embryos tested (blue arrowheads, lanes labeled 3,4,5, bottom gels).

Immunohistochemical analysis using the working anti-Brd2b peptide antibody shows
the presence of maternal Brd2b protein in all stages of oocyte, with dramatic changes in
localization over time (Figure 2E). Brd2b is dispersed throughout the cortical cytoplasm
in stages I and II, gradually concentrated around the germinal vesicle (GV) by early stage
III, and finally, by late stage III–stage IV when the GV breaks down, strikingly localized
around the micropyle, a specialized follicle cell that marks the future animal pole. This
protein localization pattern follows the previously noted track of cognate brd2b mRNA in
staged oocytes, but differs dramatically from the path followed by paralogous brd2a mRNA
and protein, both of which end up in the peripheral cortex just inside plasmalemma of the
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oocyte [25]. Thus, similarly to its paralog, Brd2b is spatially regulated during oogenesis,
but it obtains a strikingly different endpoint position.
Finally, we used the anti-Brd2b peptide antibody to assess the efficacy of Brd2b
antisense morpholino knockdowns (described in the next section) and saw reduced levels
of Brd2b-L (>150 kD) by western blot (Figure 2F,G; ~3-fold reduction in morphants, ImageJ
quantification; see the Figure 2 legend and the Materials and Methods Section).

Figure 2. Anti-Brd2b peptide antibody detects major protein products in zebrafish embryos and oocytes, that are reduced in
brd2bMO morphants. (A,B) Western blot (A) of total ovary (ov) and staged embryos (4 h, 24 h, 48 h) probed with anti-Brd2b
peptide antibody. Blot was prestained (B) to assess total protein and relative loading across lanes. Total ovary samples
often show a large amount of high molecular weight staining corresponding to yolk proteins that make up predominant
products in this tissue; nevertheless, these do not interfere with the detection of Brd2b. A product over 150 kD is consistently
detected in ovaries and 48 hpf embryos and sometimes faintly in 4 and 24 hpf embryos (top arrowheads in A); a product
between 50 and 75 kD is also consistently detected in 48 hpf embryos (bottom arrowhead) and sometimes also in 4 hpf
and 24 hpf embryos (see Supplementary Figure S1). (C,D) Duplicate blot of A probed with anti-Brd2b peptide antibody in
the presence of peptide antigen for peptide competition assay (C). The blot was prestained (D) to assess total protein and
relative loading across lanes before antibody + peptide incubation. Peptide competition prevents all antibody signals on blot
(C), supporting specificity of antibody for Brd2b epitope. Prestaining of blot using Memcode protein stain (D) assures that
lack of anti-Brd2b signal in C is due to peptide competition rather than lack of protein in lanes. (E) Immunohistochemical
analysis of staged oocytes (I–IV) and higher magnification stage IV oocyte (IV) using anti-Brd2b peptide antibodies, and
showing eventual localization to the micropyle and future animal pole. (F,G) Western blot to assess efficacy of brd2bMO
morpholino knockdown. Twenty-four hours post-fertilization embryo treatment groups: uninjected (wt), control 5-base
mismatch morpholino-injected (mis5), and brd2bMO1-injected (2bMO), probed with anti-Brd2b peptide antibody (F). The
blot was prestained (G) to assess total loading and relative loading across lanes. When relative loading is taken into account,
there is a 3-fold reduction in Brd2b (~150 kD band) in brd2bMO-treated embryos (2ng total) as measured by ImageJ (FiJI)
using band pixel densities (see Methods). Anti-Brd2B peptide antibody used in all immunoblot experiments in this study
was raised against an antigenic epitope between NLS and ET (see Materials and Methods), and detects only the long isoform
(Brd2b-L). Bottom edges of Western blots are indicated by horizontal line in (A, C and F). mw = Precision plus dual color
molecular weight standard (BioRad); ch = Precision plus Western Chemiluminescent marker (BioRad).

J. Dev. Biol. 2021, 9, 46

13 of 36

Figure 3. Brd2b knockdown results in reduced hindbrain, ill-defined MHB region, and trunk abnormalities similar to Brd2a
morphants, but presents unique circulatory and pronephric defects. Brightfield images of 24 hpf prim 5 embryos (A–F),
and larvae at 6 days (H–J). Lateral views of head and trunk of representative embryos from indicated treatment groups:
(A) uninjected; (B) brd2bMO1-injected; (C) Brd2bMO1 + HsBrd2RNA co-injected; (D) Brd2MO2-injected; (E) Crispr-Cas9brd2b-disrupted; and for comparison, (F) paralog brd2aMO-injected. In A) mhb = midbrain-hindbrain; pd = pronephric
duct; c = cloaca; pbi = peripheral blood island. Head and trunk defects in morphants and Crispr-Cas9-treated embryos
are indicated by black arrows, and include reduced brain and ill-defined MHB region, misformed pronephric duct, and
disorganized PBI. These defects are substantially rescued by co-injection of human Brd2 RNA, recapitulated by a nonoverlapping anti-brd2b morpholino (MO2), and phenocopied by Crispr-Cas9 disruption, showing gene-specificity of
observed effects. (G) Crispr-Cas9 brd2b target validation, showing intact PCR products from wildtype (lane 1, wt) and
Crispr-disrupted (lane 2, 2b) brd2b locus; wildtype PCR product treated with mismatch-detecting resolvase (lane 4, wt+)
and untreated (lane5, wt−); Crispr-disrupted PCR product treated with resolvase (lane 6, 2b+) and untreated (lane 7, 2b−).
Crispr-disrupted brd2b locus treated with resolvase shows cleavage products (asterisk highlighting lane 6), while wildtype
locus remains intact, indicating that Crispr-Cas9 targeted designated sequences in the brd2b locus. Pixel density of the
600 bp intact product band is reduced from 980 in untreated (lane 7) to 528 in treated (lane 6) Crispr-disrupted embryos,
indicating close to 50% efficacy (see Methods). (H) Six day old morphant larvae injected at 2 cell stage with 1 ng brd2bMO1,
or (I,J) 2ng brd2bMO1, illustrating dosage-dependent severe heart edema and trunk deformities, due to nearly complete
lack of blood circulation. See Table 1 for population morphology data from these studies. See Supplementary Figure S1 for
HsBrd2 RNA control embryos images.

In addition to the morphant brain defects that were shared by the paralogs, we
found novel abnormalities that were unique to Brd2b knockdown in the ventral trunk
and circulatory system. By the prim 5 stage, brd2bMO morphants exhibit a malformed
pronephric duct with the distal tip cloaca often clogged by a terminal plug of “extra”
cells, rather than opening to the outside (Figure 3B,D,E vs. Figure 3A,C; trunk insets,
top arrows; also, refer to diagram of pronephros in Figure 6N). In addition, the region
just posterior to the duct and ventral to the nerve cord (see Figure 3A, pbi) is sometimes
disorganized or clumpy compared to its uniform and granular appearance in wildtype
(Figure 3B,D,E vs. Figure 3A,C; trunk insets, bottom arrows). This region is home to
the peripheral blood island (PBI), where a transient wave of hematopoiesis is ongoing
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during segmentation [43]. Heartbeat in terms of rate and strength is impaired from prim
5 onward as well. These defects are phenocopied by Crispr-Cas9 disruption of brd2b
(Figure 3E; trunk inset, arrows) and rescued substantially by co-injection with HsBrd2RNA
(Figure 3C; trunk inset). Population data confirm that differences between treatment
groups for trunk and heart defects are statistically significant (Table 1, brd2bMO single
knockdown and brd2bMO1 +/− HsBrd2RNA rescue, p < 0.0001). Although brd2aMO
morphants show post-anal trunk defects with disrupted often “vacant” PBI tissue at a
higher frequency, they lack the clogged pronephric duct defect characteristic of brd2bMO
morphants (Figure 3F vs. Figure 3B,D; trunk inset, upper arrows for pbi). As development
proceeds, brd2bMO morphants display progressively slower heart rates, weaker heartbeats,
and severe pericardial edema. Eventually, complete lack of circulation leads to degeneration
of the trunk (Figure 3I,J) and death typically by 5–7 dpf. This contrasts with brd2aMO
morphants, which can survive up to two weeks or more with continued circulation [27].
Table 1. Population morphology data: RNA rescue, knockdown and co-knockdown studies.
% Brain Defect a

Treatment

% Pbi Defect b

% Duct Defect c

% Circ Defects d

brd2bMO1 +/− HsBrd2RNA rescue e
control
12.5
0
0
0
HsBrd2RNA
11.5
0
7.7
0
brd2bMO1
100
100
100
50
brd2bMO1 + HsBrd2RNA
20
8.6
17.1
5.7
Chi-square Contingency, Fisher’s Exact Test: p < 0.0001 for all four defects.
Correspondence Analysis: [wildtype: control, RNA, brd2bMO+HsRNA] [defect: 2bMO], for all four parameters.
brd2bMO single knockdown corroboration f
0
0
0
0
0
0
100
25.8
88.7
100
24.2
100
100
21
100
Chi-square Contingency, Fisher’s Exact Test: p < 0.0001 for all four defects.
Correspondence Analysis: [wildtype: control, mis5] [defect: MOs, Crispr] for brain;
[wildtype: control, mis5] [defect: MOs, Crispr] for PBI, duct, circulation

control
mis5
2bMO1
2bMO2
Crispr2b

brd2aMO/brd2bMO co-knockdown f
0
0
0
100
80
0
100
26.7
91.7
5
0
0
Chi-square Contingency, Fisher’s Exact Test: p < 0.0001 for all four defects
Correspondence Analysis: [Wildtype: control, 2aMO+2bMO] [Defect: 2aMO, 2bMO] for brain;

control
2aMO1
2bMO1
2aMO1 + 2bMO1

0
0
93.7
100
100

0
0
96.7
0

[Wildtype: control, 2aMO+2bMO, 2bMO] [defect: 2aMO] For PBI;
[Wildtype: control, 2aMO+2bMO, 2aMO] [defect: 2bMO] for duct, circulation
a
e

reduced brain, ill-defined mhb region b disorganized or vacuous pbi c plugged or enlarged cloaca d severely reduced or absent circulation
20–40 embryos per treatment; 2bmo, 2 ng; 2amo, 4 ng; hsbrd2 rna 250 pg f 60 embryos per treatment; 2bmo, 2 ng; 2amo, 4 ng.

Similarly to what we observed in Brd2a knockdown studies [27], brd2bMO morphant
defects show variable expressivity and, to a lesser degree, incomplete penetrance; both
the severity and penetrance of defects increase with dose for brd2bMO1 (p < 0.0001, chi
square contingency and Cochran–Mantel–Haenszel tests). For instance, at 0.5 ng brd2bMO1,
76.9% of morphants show wildtype brain, while 19.2% show mild and 3.8% moderate
brain defects; at 2 ng brd2bMO1, 0% morphant brains are wild type, while 78.9% are mildly,
15.8% moderately, and 5.3% severely defective; at 6 ng, 0% morphants are wild type, 31.5%
show mild, 52.6% moderate, and 15.7% severe brain defects. Pooling mild, moderate,
and severe morphant phenotypes together, we typically see 100% penetrance of the brain
defect, between 88 and 100% penetrance of the pronephric duct and circulation defects,
and around 25% penetrance of the peripheral blood island defect, when using 2 ng of either
brd2bMO (Table 1, brd2bMO single knockdown). Crispr-Cas9 disruption of the brd2b locus
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results in 100% penetrance and moderate to severe brain, duct, and circulatory defects,
while PBI abnormalities remain at 21% penetrance and moderate to mild severity.
Taken together, these studies show that brd2b exhibits both shared and unique developmental functions with its previously studied paralog brd2a, in expression domains such
as the germline and the embryonic brain and ventral trunk. Significantly, brd2b produces a
tissue- and stage-specific transcript variant and possibly several protein isoforms, and is
required uniquely for the proper formation of the pronephros and cloaca and for ongoing
blood circulation in developing embryos.
3.4. Brd2b Knockdown Increases Cell Death in the CNS of Prim 5 Morphant Embryos but Reduces
Cell Death in the Cloaca of the Pronephros
Since we knew that a deficiency of Brd2a leads to similarly reduced and defective
brains as seen here, and also to dramatic increases in neural cell death [27], we examined
levels of apoptosis in Brd2b-deficient morphants as well. A minimum of 30 embryos
per treatment group were subjected to whole-mount fluorescent TUNEL assay at prim 5
followed by laser-scanning confocal microscopy to produce optical sections and maximum
projection images. Six to ten representative embryos from each treatment group were then
used in quantitative analysis of apoptotic nuclei. Three sets of tests were conducted to
assess the authenticity of cell death in morphants: set 1, Rescue by HsBrd2 RNA, to test
gene-specificity; set 2, Corroboration by independent means, to obtain the same effects without morpholinos; and set 3, p53-independence, to test for off-target apoptotic effects [44].
Representative maximum projection images from these experimental sets are shown in
Figure 4 and Supplementary Figure S3 and accompanying quantitative population data are
shown in Figure 5A–C (see Figure 5 legend for full description of treatment groups). As is
the case for Brd2a knockdown [27], cell death is increased dramatically in the brains and
dorsal spinal cords of prim5 morphants compared to NON-brd2bMO-injected or uninjected
control embryos in every set (Figure 4A,E,F vs. Figure 4B,G; see Supplementary Figure S3
for HsRNA alone; Figure 5 A,B,C; 2bMO vs. control, HsRNA, or p53MO, respectively). The
increased cell death in Brd2bMO morphant CNS is rescued substantially by co-injection of
HsBrd2RNA, showing excess death to be a gene-specific effect (Figure 4B vs. Figure 4C;
Figure 5A, 2bMO1 vs. 2bMO1 + HsRNA). Quantitative data show, on average, 707 apoptotic nuclei in the brains of brd2bMO morphants compared with 332 for uninjected and 334
for brd2bMO + HsRNA co-injected embryos (p < 0.0001, one-way ANOVA, Tukey’s HSD).
Conversely, co-injection with p53MO does not substantially reduce the excess cell death
observed (Figure 4G vs. Figure 4H; Figure 5C, 2bMO1 vs. 2bMO1 + p53MO), showing
that excess death is not due to non-specific, off-target, p53-dependent effects sometimes
observed with morpholino treatment [44]. Quantitative data show similar averages of
apoptotic nuclei in the brains of brd2bMO-injected (581) and brd2bMO + p53MO co-injected
(500) embryos, while uninjected and p53MO-injected embryos show, on average, between
306 and 288 apoptotic nuclei, respectively (p < 0.0001, one-way ANOVA, Tukey’s HSD).
Finally, the dramatic increase in cell death seen in the CNS of morphants is recapitulated
with Crispr-Cas9 disruption of the brd2b locus, supporting the claim that increased apoptosis is the result of Brd2b deficiency rather than general morpholino toxicity (Figure 4D,B,G;
Figure 5B, 2bMO1, 2bMO2, Crispr2b vs. control). Quantitative data show, on average,
708 apoptotic nuclei in the brains of both brd2bMO1 and brd2bMO2 morphants and a similar average of 783 apoptotic nuclei in Crispr-disrupted embryos, while uninjected control
embryos show, on average, 329 apoptotic nuclei (p < 0.0001, one-way ANOVA, Tukey’s
HSD). Thus, deficiency during development of either Brd2a or Brd2b paralog results in dramatic increases in cell death in the CNS of segmentation stage embryos, likely accounting
for a substantial part of the gross morphological defects observed in the developing brain.

J. Dev. Biol. 2021, 9, 46

16 of 36

Figure 4. Brd2b knockdown increases cell death in the CNS of prim 5 morphant embryos but reduces cell death in the cloaca of the pronephros. Dark-field images of representative 24 hpf prim5
embryos treated as indicated and after TUNEL assay for apoptotic nuclei. Panels (A–D) (heads
and trunks) show treatment groups for testing gene-specificity of apoptotic effects: (A) uninjected;
(B) brd2bMO1-injected; (C) brd2bMO1 + HsBrd2RNA-injected; and (D) Crispr-Cas9-brd2b-disrupted
embryos. HsBrd2RNA co-injection rescues, while Crispr-Cas9 treatment phenocopies, excess apoptosis in the brain and trunk overall of morphants, showing effects are specific to brd2b. Arrows
indicate specific regions of reduced apoptosis at the cloaca (upper arrows) and increased apoptosis in
the PBI (lower arrows) in the ventral trunk of morphant and Crispr-Cas9-treated, but not control or
rescued embryos. Panels E–H (heads and trunks) show treatment groups for testing p53-dependent
off-target effects: (E) uninjected; (F) p53MO-injected; (G) brd2bMO1-injected; and (H) brd2bMO1−
+ p53MO co-injected. p53MO co-injection does not abrogate excess apoptosis in morphants, ruling
out off-target effects as the cause of cell death. See Figure 5 for quantitative TUNEL data from these
studies. See Supplementary Figure S2 for images on HsBrd2 RNA control embryos.
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Figure 5. Quantitative TUNEL analysis of cell death: knockdown, co-knockdown, and antagonism studies. Cell death levels
were measured in brd2bMO morphants and control embryos under various treatments using fluorescence TUNEL assay
followed by quantitative laser-scanning confocal microscopy. The number of apoptotic nuclei in multiple optical sections
from the brains of three to ten embryos per treatment, depending on experiment, were compared (see Methods for details).
(A) RNA rescue treatments: brd2bMO1-injected (2bMO1), human Brd2 RNA-injected (HsRNA), brd2bMO1 + human Brd2
RNA-injected (2bMO+HsRNA), and uninjected (control). Means vary significantly by treatment (p < 0.0001, one-way
ANOVA, Tukey’s HSD), with the greatest difference between 2bMO1 and all other treatments and no significant difference
between “control” and “2bMO+HsRNA”, indicating effective rescue by exogenous human Brd2 RNA. Cell death numbers
for HsBrd2 RNA-injected controls were obtained from embryos from a separate clutch but reflect what we have consistently
seen over multiple independent trials. (B) brd2bMO knockdown corroboration treatments: brd2bMO1-injected (2bMO1),
brd2bMO2-injected (2bMO2), Crispr-Cas9-brd2b disruption (Crispr2b), and uninjected (control). Means vary significantly by
treatment (p < 0.0001, one-way ANOVA, Tukey HSD), with Crispr2b, 2bMO1 and 2bMO2 all showing effects significantly
greater than “control”; 2bMO1 and 2bMO2 show equivalent and moderate effects, while Crispr2b shows the greatest
effect. Thus, three independent treatments targeting brd2b result in similarly increased cell death levels, showing genespecificity of effect. (C) p53-dependent off-target effect treatments: brd2bMO1-injected (2bMO1), brd2bMO1 + p53MO
co-injected (2bMO1 + p53MO), uninjected (control), and p53MO-injected (p53MO). Means vary significantly by treatment
(p < 0.0001, one-way ANOVA, Tukey’s HSD), with no significant difference between 2bMO1 and “2bMO1 + p53MO” or
between “control” and p53MO, but significant differences between the two pairs, indicating excess apoptosis is brd2bspecific, and not the result of p53-dependent off-target effects. (D) Co-knockdown treatments: brd2aMO1-injected (2aMO1),
brd2bMO1-injected (2bMO1), brd2aMO1 + brd2bMO1 co-injected (2aMO+2bMO), and uninjected (control). Means vary
significantly by treatment (p < 0.0001, one-way ANOVA, Tukey’s HSD), with “control” and “2aMO + 2bMO” not significantly
different from each other and both significantly different from either 2bMO1 or 2aMO1; 2bMO1 shows a greater effect
than 2aMO1. Simultaneous knockdown of both paralogs suppresses excess cell death observed in single knockdowns
of either paralog and restores wild type levels of apoptosis. Panels (E–H): Rescue-Enhancement studies using zebrafish
brd2a and brd2b-L in vitro-synthesized RNAs (not human Brd2) tested functional antagonism between paralogs at the
level of apoptosis. (E) brd2bMO rescue treatments: brd2bMO2 (2bMO2), brd2b-LRNA (2bRNAL), brd2bMO2 + brd2b-LRNA
(2bMO2 + 2bRNAL), and uninjected (control). Means vary significantly by treatment (p-0.0286, one-way ANOVA, Tukey’s
HSD), with “2bMO2+2bRNAL” closer to “control” in effect (p = 0.8407) than either 2bMO1 (p = 0.1319) or 2bRNAL
(p = 0.0295), indicating partial rescue of the brd2bMO morphant defect.

J. Dev. Biol. 2021, 9, 46

18 of 36

(F) brd2bMO enhancement treatments: brd2aRNA-injected (2aRNA), brd2bMO2-injected (2bMO2), brd2aRNA + brd2bMO2
co-injected(2bMO2+2aRNA), and uninjected (control). Means vary significantly by treatment (p = 0.0008, one-way ANOVA,
Tukey’s HSD), with “2bMO2+2aRNA” giving significantly greater effect compared to “control” (p = 0.0009) than either
2bMO2 (p = 0.2405) or 2aRNA (p = 0.9151). (G) brd2aMO rescue treatments: brd2aMO1-injected (2aMO1), brd2aRNA-injected
(2aRNA), brd2aMO1 + brd2aRNA co-injected (2aMO1 + 2aRNA), and uninjected (control). Means vary significantly be
treatment (p = −0.0176, one-way ANOVA, Tukey’s HSD), with “2aMO1 + 2aRNA” closer to “control” in effect (p = 0.9985)
than either 2aRNA (p = 0.3286) or 2aMO1 (p = 0.0.0294), indicating partial rescue of the brd2aMO morphant defect.
(H) brd2aMO enhancement treatments: brd2aMO1-injected (2aMO1), brd2b-LRNA-injected (2bRNAL), brd2aMO1 + brd2bLRNA co-injected (2aMO1 + 2bRNAL), and uninjected (control). Means vary significantly by treatment (p = 0.0084, one-way
ANOVA, Tukey’s HSD), with “2aMO1+2bRNAL” giving significantly greater effect compared to “control” (p = 0.0085), than
either 2aMO (p = 0.3433) or 2bRNAL (0.9342). Note: for experiments in A, B, and D, apoptotic cell counts were obtained
from 55 to 60 optical sections from 6 to 10 embryos per treatment; for experiment C, from maximum projection images
from 3 embryos per treatment; for experiments (E–H), from 35 optical sections from 3 to 5 embryos per treatment. Green
diamonds: confidence interval (95%) for group means with standard error. Black line: grand sample mean. Black circles:
comparison circles for absolute differences of group means.

Since Brd2b knockdown results in morphological defects of the ventral trunk, including a malformed and clogged pronephric duct and disorganized PBI, we looked in this
region to assess cell death. As in Brd2a knockdowns [27], we consistently see excess cell
death overall in the post-anal tail, PBI, and dorsal spinal cord of brd2bMO morphants
(Figure 4B,D vs. Figure 4A,C; trunk insets, bottom arrows). Quantitative population data
show, on average, 151 apoptotic nuclei in this region in brd2bMO morphants, compared
to 75 in uninjected embryos and 86 in HsRNA-rescued morphants (p < 0.0001, one-way
ANOVA, Tukey’s HSD). However, in terms of spatial distribution, we observe uniquely
in brd2bMO morphants a decrease in cell death, sometimes along the ductal tube, but most
consistently and prominently at the very distal cloaca, which normally would undergo cavitation via apoptosis to form the opening of the pronephric duct to the outside (Figure 4B,D
vs. Figure 4A,C; trunk insets, top arrows). These observations suggest lack of cell death at
the cloaca may be the cause of the plug of excess cells found there in Brd2b knockdowns,
while increased overall cell death contributes to irregularities seen in the spinal cord,
somites and PBI tissue of these morphants. Taken together, these findings show that as
with Brd2a, paralog Brd2b is a major regulator of cell death in development and is capable
of bimodal action—that is, it can act both as a pro-apoptotic and an anti-apoptotic factor,
depending on context [27].
3.5. Patterning of pax2a (+) Spinal Interneurons and Distribution of Pronephric Cells Is Disrupted
in Both brd2b and brd2a Morphants
In our previous study [27] we showed that zebrafish brd2a is necessary for the proper
expression of some of the genes that pattern the MHB region (eng2a and pax2a) and the
hindbrain (krox20/egr2). We also noted that pax2a-expressing spinal interneurons show
abnormal patterning and numbers in brd2aMO morphants compared to control embryos,
and thought it plausible that a HOX/Brd2a pathway might be involved. Normally, spinal
interneurons derived from the ventral spinal cord are symmetrically paired on either
side of the midline, and homeobox (Hox) genes are known to regulate their patterning and
periodicity along the A–P axis [45]. To assess the effects of paralog Brd2b deficiency on
these same parameters, we subjected a total of at least twenty prim 5 wildtype and brd2bMO
morphant embryos per probe to hybridization In situ to eng2a, pax2a, and krox20 for brain
patterning defects and to pax2a for interneuron pairing defects (Figure 6A–L). In contrast
to brd2aMO morphants, brd2bMO morphants show no differences in brain expression
for the patterning genes tested (Figure 6A,D,G and Figure 6B,E,H vs. Figure 6C,F,I).
However, when pax2a-expressing spinal interneurons were analyzed for matched pairing
on either side of the nerve cord, we found a greater frequency of mispairing in brd2bMO
morphants compared to uninjected or control-injected embryos (Figure 6J,K vs. Figure 6L),
as observed in brd2aMO morphants [27]. In fact, quantitative population data obtained
through anti-Pax2a immunofluorescence confocal imaging show, on average, 65.4% of
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spinal interneurons are unpaired in brd2bMO morphant embryos, compared to only 3.1%
unpaired interneurons in controls (Figure 6M,N; p < 0.0001, chi square contingency, Fisher’s
exact tests). This displays a similar trend to what we saw previously in brd2aMO morphants,
which show unpaired interneurons 83% of the time, with 34.5% showing an unrecognizable
pattern, compared to uninjected or control-injected embryos, which show, on average,
mispairing only 3% of the time [27]. Thus, while patterning genes in the hindbrain and
MHB region are misexpressed only in brd2a morphants, HOX-regulated patterning of
spinal interneurons is disrupted by deficiencies in either paralog.
Since the developing pronephros appears malformed and the cloaca is plugged with
excess cells uniquely in brd2bMO morphants, we wanted to examine the behavior of
pronephric cells more closely. Pronephric progenitor cells normally express Pax2a, a key
marker that distinguishes them from the blood cell progenitors that arise simultaneously
from a shared field in the intermediate mesoderm [46]. Immunofluorescence staining
followed by confocal imaging allowed us to assess the position and number of Pax2a(+)
cells in individual segments of the developing pronephros (refer to Figure 6O for diagram)
and compare them in prim 5 control embryos and brd2bMO morphants (Figure 6P,Q). In
control embryos, Pax2a(+) presumptive pronephric cells are seen in the ventral trunk, lined
up and evenly distributed along the length of the duct through the cloaca, where they form
the opening to the outside (Figure 6P,Q; wt). In brd2bMO morphants, however, these same
Pax2a(+) cells are unevenly distributed, with a paucity of cells in the middle segments of the
duct, and an overabundance of cells occluding the cloaca at the very distal tip (Figure 6P,
wt vs. brd2bMO1, arrows). Quantitative population data support these observations:
brd2bMO morphants exhibit fewer Pax2a(+) cells in the subregion containing the proximal
straight tube (PST), the distal early tube (DE), and the distal late tube (DL), but significantly
more Pax2a(+) cells in the cloaca (C), compared to control embryos (Figure 6R, 2bMO vs.
none; p < 0.0001, one-way ANOVA, Tukey’s HSD). No difference in cell number is seen
between controls and brd2bMO morphants in the region of the glomerulus or the proximal
convoluted tube (G/PCT) (Figure 6R, 2bMO vs. none; p = 0.3971, one-way ANOVA, Tukey’s
HSD). As stated in the last section, cell death is especially—and consistently—reduced at
the cloaca of the pronephros in brd2bMO morphants, and sometimes along the length of
the duct. While reduced cell death may thus directly explain the excess cells at the cloaca,
it cannot directly account for the reduced number of Pax2a(+) cells in midsections of the
duct. It is possible that other mechanisms, such as reduced mitosis, misfating, or aberrant
migration of pronephric precursors, might be at work in this region.
Strikingly, knockdown of paralog Brd2a results in almost opposite effects to those
described above: there is a dramatic excess of Pax2a(+) presumptive pronephric progenitor
cells along the entire length of the duct, but not at the distal tip, where the cloaca remains
unclogged (Figure 6Q, wt vs. brd2aMO1, span between arrows). These data corroborate
our previous In situ RNA hybridization studies, where brd2aMO morphants had too many
pax2>a(+) cells to count in this region 76% of the time, whereas in uninjected or control
injected embryos this occurred only 17% of the time [27]. Interestingly, cell death levels
along the duct appear normal in these morphants, implying the involvement of other
underlying mechanisms [47]. Overall, in the developing pronephros, paralogs brd2a and
brd2b appear mostly to exert opposite effects on the number and distribution of Pax2a(+)
presumptive pronephric progenitors during the period when the duct is being built.
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Figure 6. MHB expression of pax2a, eng2a and krox20 mRNA is normal, but patterning of pax2a (+) spinal interneurons and pronephric
cells is disrupted, in brd2b morphants. Panels (A–L): Brightfield images of representative 24 hpf prim5 control and morphant embryos
assayed by In situ hybridization for expression of patterning genes at the MHB region (A–I) and in spinal interneurons (J–L). Uninjected
embryos (wt; A,D,G,J), embryos injected with control brd2b-5-base mismatch morpholino (mis5MO; B,E,H,K), and embryos injected
with brd2bMO (brd2bMO1; C,F,I,L) were assayed for eng2a (A,B,C), krox20 (D,E,F,), and pax2a (G,H,I; J,K,L) expression. No differences
in patterning gene expression at the MHB region are detected. Using pax2a(+) as a marker for spinal interneurons reveals mispairing on
either side of the midline in morphants (J,K vs. L, gaps between lines). (M) Immunofluorescence with anti-Pax2a antibodies to visualize
interneurons on either side of spinal cord, dorsal views of maximum projection confocal images. Representative control uninjected
(wt) and brd2bMO1-injected (2bMO) embryos are shown with symmetrically paired interneurons linked by white lines; unpaired
interneurons appear solo on one side of the central spinal cord. (N) The number of paired “P” vs. unpaired “U” interneurons in six
embryos per treatment group (uninjected controls = none; brd2bMO-injected = 2bMO) was analyzed by chi-square contingency and is
shown as a box plot (p < 0.0001). While, on average, only 3% of interneurons are unpaired in wild type, about 65% are unpaired in
brd2bMO morphants. Panels O–R: Analysis of Pax2a(+) pronephric precursor cells in the developing duct in brd2bMO and brd2aMO
morphants by quantitative immunofluorescence. (O) Diagram of pronephric duct segments: G, glomerulus; N, neck; PCT, proximal
convoluted tube; PST, proximal straight tube; DE, distal early tube; DL, distal late tube; C, cloaca. (P) Pax2a(+) immunofluorescence
in uninjected (wt) and brd2bMO morphants (brd2bMO1). (Q) Pax2a(+) immunofluorescence in uninjected (wt) and brd2a morphants
(brd2aMO1). Paralogs show opposite effects on distribution of Pax2a(+) pronephric cells (arrows). brd2b morphants show fewer cells in
the more distal parts of the tube (PST, DE, DL) but more cells at the very end cloaca (C), compared to wild type, while brd2a morphants
show excess cells along the tube, and a normal number of cells at the cloaca. (R) Quantitation of distribution of Pax2a(+) cells in
uninjected (none) and brd2bMO1-injected embryos (2bMO), by pronephric segment. Boxplot of ANOVA and paired t-tests shows
significant differences in the predicted direction between these two treatment groups in segments PST/DE/DL (p < 0.0001,) and in C
(p < 0.0001), but not in G/PCT (p = 0.3971).
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3.6. Co-Knockdown of Brd2a and Brd2b Paralogs Restores Wild Type Phenotype to Both Brain and
Pronephros of Morphant Embryos at Prim 5
Given that zebrafish paralogs brd2a and brd2b show substantially overlapping expression domains during embryogenesis, have the potential (at least theoretically) to form
heterodimers via their respective bromodomains [48], and, when deficient, result in both
similar and sometimes seemingly opposite defects, we wondered whether the paralogs
interacted genetically. To test this, we performed co-injections of brd2aMO and brd2bMO
to create double knockdowns and assessed the resultant morphant phenotypes. Single
knockdowns were created by injecting 2–4 cell embryos with either 2 ng of brd2bMO
or 4 ng of brd2aMO, the usual doses we use for each morpholino, respectively; double
knockdowns were created by injecting a mix of brd2bMO + brd2aMO at the same individual
concentrations. A total of 60 embryos per treatment were assessed at prim 5 stage for
morphological defects. Representative images of embryos from each treatment group (wt,
brd2bMO, brd2aMO, and brd2bMO+brd2aMO mix) are shown in Figure 7A–D; quantitative
population data are shown in Table 1, brd2a/brd2b co-knockdown. Strikingly, co-injection of a
mix of brd2bMO1+ brd2aMO1 suppresses the morphant brain and ventral trunk phenotypes
and restores wild type morphology (Figure 7B,C vs. Figure 7A,D). This includes restoration
of brain size, MHB region definition, organization of the PBI, and open pronephric cloaca.
Quantitative population data support these observations (Table 1, brd2a/brd2b co-knockdown,
p < 0.0001). We then used TUNEL assay to assess the effects of double knockdown on levels
of cell death, and found that co-injection of morpholinos from the two loci restores wild
type levels of apoptosis in both the CNS and ventral trunk of morphants—in particular,
we see reduced cell death overall in the brains and trunks of co-knockdowns compared
to either single gene morphant, but increased cell death at the cloaca of co-knockdowns
compared to brd2bMO morphants (Figure 7F,G vs. Figure 7E,H). Quantitative analysis
of apoptotic cell counts using optical sections through the brain of seven representative
embryos from each treatment group indicates that single knockdown morphants display,
on average, between 600 and 700 apoptotic nuclei, whereas co-injected embryos display,
on average, around 300 apoptotic nuclei, comparable to uninjected embryos (Figure 5D;
p < 0.0001, one-way ANOVA, Tukey’s HSD). When apoptosis was measured in the postanal trunk in toto, including the pronephros, PBI, dorsal spinal cord and somites, double
knockdowns show restoration to lower levels of cell death overall comparable to wild type
(average 78 vs. 137–150 apoptotic nuclei, in double or uninjected vs. single knockdown
morphants, respectively; p < 0.0001, one-way ANOVA, Tukey’s HSD). However, apoptosis
increased in the cloaca in double-knockdowns compared to brd2bMO morphants, presumably opening the ductal exit (Figure 7F vs. Figure 7H, trunk, white arrow in Figure 7F).
Double knockdown also corrects the aberrant distribution of Pax2a(+) cells along the length
of the duct and at the cloaca observed in single knockdowns (Figure 7I–L; cloaca, white
arrow in left panels; ductal tube, span between white arrows in right panels). Whereas
brd2bMO morphants show clogged cloaca and sparse distribution of Pax2a(+) cells along
the mid-sections of the ductal tube (Figure 7J), and brd2aMO morphants show open cloaca
and excess Pax2a(+) cells along the ductal tube (Figure 7K), both wildtype and double
knockdown embryos show open cloaca and more even distribution of Pax2a(+) pronephric
cells along the duct (Figure 7I,L). Finally, double knockdown suppresses the mispairing
defect of VNC-derived spinal interneurons seen in each single knockdown, increasing the
number and pairing of interneurons to near wildtype levels (Figure 7M,P vs. Figure 7N,O;
pairs indicated by lines in each panel).

J. Dev. Biol. 2021, 9, 46

22 of 36

Figure 7. Co-knockdown of Brd2a and Brd2b suppresses morphant defects in both brain and pronephros of morphant
embryos at 24 hpf. Double knockdown was used to test for genetic interaction between paralogs. Panels (A–D): Brightfield images of head and trunk of representative 24 hpf prim5 embryos from indicated treatment groups assessed for
morphology: (A) uninjected, (B) brd2bMO-injected, (C) brd2aMO-injected, and (D) brd2bMO + brd2aMO co-injected.
Panels (E–H): Darkfield images of representative embryos from the same treatment groups assessed by TUNEL assay for
apoptotic nuclei: (E) uninjected, (F) brd2bMO-injected, (G) brd2aMO-injected, and (H) brd2bMO + brd2aMO co-injected.
Co-injection of MOs from each paralog suppresses morphant defects in both morphology and cell death in the brain and
trunk, indicating genetic interaction with functional antagonism between paralogs. Black arrows indicate reduced brain,
ill-formed MHB region, disorganized PBI common to both morphants (B,C), and plug of excess cells at the cloaca unique
to brd2bMO morphants (upper arrow in B, trunk). White arrows show increased apoptosis in brain and PBI common to
both morphants (F,G, head; G, trunk), while lack of apoptosis is seen at the cloaca only in brd2bMO morphants (F, trunk).
See Table 1 for population morphology data and Figure 5 for quantitative TUNEL data. Panels (I–L): Darkfield images of
pronephric duct in trunks of representative 24 hpf prim 5 embryos from the indicated treatment groups assessed for Pax2a(+)
cells by immunofluorescence: (I) uninjected, (J) brd2bMO-injected, (K) brd2aMO-injected, and (L) brd2bMO + brd2aMO
co-injected. Cloacal opening is indicated by white arrow in left panels. Distribution along the ductal tube of Pax2a(+)
pronephric precursor cells is highlighted between white arrows in right panels. Co-knockdown suppresses morphant defects
of each paralog, bringing distribution of cells along the duct and at the cloaca closer to wildtype. (see also Figure 6O,P,Q).
Panels (M–P): Darkfield images of spinal interneurons along dorsal trunks of representative 24 hpf embryos from the
indicated treatments groups assessed for Pax2a(+) cells by immunofluorescence: (M) uninjected, (N) brd2bMO-injected,
(O) brd2aMO-injected, and (P) brd2bMO + brd2aMO co-injected. Co-knockdown suppresses the morphant mis-pairing defect
of each paralog, and restores interneuron number and pairing to near wildtype levels. Lines connect symmetrically paired
neurons; unpaired neurons appear solo on one or the other side of the central nerve cord.

Thus, in the double knockdown, the deficiency phenotypes of each paralog are suppressed by the concurrent deficiency of the other paralog. Taken together, these results
suggest some sort of genetic interaction, direct or indirect, with functional antagonism,
is at work between the two paralogs brd2b and brd2a during development of the CNS,
pronephros, and the PBI in zebrafish embryos.
3.7. Enhancement of Morphant Brain Phenotypes by Injection of Paralogous RNA Corroborates
Genetic Antagonism between brd2a and brd2b Loci
Given that Brd2b/Brd2a double knockdown restores wild type phenotype, we reasoned that the proposed genetic interaction between the two paralogs might involve
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functional antagonism and/or some required stoichiometry between their respective gene
products. To explore this idea, we conducted a series of genetic rescue and enhancement
studies using combinations of morpholinos and in vitro-synthesized mRNAs aimed at
testing the following predictions: (1) brd2bMO morphant phenotypes will be rescued by
co-injection of cognate brd2b RNA but enhanced by co-injection of paralogous brd2a RNA;
and conversely, (2) brd2aMO morphant phenotypes will be rescued by co-injection of brd2a
RNA but enhanced by co-injection of paralogous brd2b RNA. Up to this point, we had used
in vitro-synthesized human Brd2 RNA in our rescue experiments to verify the specificity
of the original brd2a and brd2b morpholino knockdowns. In fact, the human transcript
was able to rescue to a notable degree the knockdown phenotypes of both Brd2 paralogs
in zebrafish [27]. However, to conduct this next set of rescue/enhancement studies, we
first cloned full-length cDNAs of both brd2a and brd2b using RT-PCR on mRNA isolated
from zebrafish embryos (see Materials and Methods). We obtained a single 3.8 kb cDNA
representing the major full-length transcript of brd2a, and two cDNAs of 3.5 kb and 1.4 kb,
representing long (brd2b-L) and short (brd2b-S) transcript variants, respectively, from the
brd2b locus. Thus, we could conduct rescue-enhancement studies using all three transcripts
derived from native zebrafish genomic loci.
To test the newly cloned zebrafish cDNAs, we first set up rescue experiments for
each paralog using full-length RNAs. Treatment groups for brd2bMO rescue (control
uninjected, brd2bMO2, brd2b-LRNA, and brd2bMO2 + brd2b-LRNA co-injected), and for
brd2aMO rescue (control uninjected, brd2aMO1, brd2aRNA, and Brd2MO1 + brd2aRNA
co-injected), were assessed for brain and trunk morphology. For quantitative population
analysis of all rescue-enhancement experiments, we counted only defects that could be
classified as moderate to severe, to avoid any ambiguity in scoring between wild type
embryos and mildly defective morphants. Representative images from these experiments
are shown in Figure 8 and quantitative population data are presented in Table 2. brd2bMO
morphant brain defects are partially rescued by co-injection of zebrafish brd2b-LRNA
(Figure 8D vs. Figure 8E; arrow), with some restoration of the rectangular dorsal width
and height of the MHB region and clearer delineation of the boundary itself. Quantitative
population data support brain rescue: brd2bMO2-injected morphants present with moderate to severe brain defects 40.4% of the time, while Brd2MO2+brd2b-LRNA co-injected
morphants present moderate/severe defects only 24.6% of the time (Table 2, 2bMO rescue
2bRNA-L_brain; p = 0.0026). Correspondence analysis clusters wild type phenotype with
[control, 2bMO+2bRNA-L] treatments and defective phenotype with [2bMO, 2bRNA-L]
treatments. Similarly, brd2aMO morphant brain defects are partially rescued by co-injection
of zebrafish brd2aRNA (Figure 8G vs. Figure 8H; arrow), with height and width of MHB
region and size of the ventricle and hindbrain partially restored. Quantitative population
data support brain rescue: brd2aMO morphants show moderate to severe brain defects
35% of the time, compared to 20% for embryos co-injected with brd2aRNA (Table 2, 2aMO
rescue 2aRNA_brain; p = 0.1416). Although above threshold for statistically significant
differences among treatments, Correspondence analysis clusters wild type with [control]
then [2aRNA, 2aMO+2aRNA] treatments, while defective phenotype is grouped more
definitively with [2aMO] treatment. Thus, knockdowns of each paralogous locus are at
least partially rescued in terms of brain defects by introduction of their full-length, cognate
zebrafish RNAs, in a fashion similar to their collective rescue by the single human Brd2
RNA [27]. We noted that injection of either zebrafish brd2b-LRNA or brd2aRNA alone into
embryos often results in mild brain defects that phenocopy morphant defects (Figure 8,
compare Figure 8B and Figure 8D; compare Figure 8C and Figure 8G; see also Table 2,
2bMO rescue-2bRNA-L_brain and 2aMO rescue-2aRNA_brain, compare RNA injections vs.
control). We believe this, in fact, supports the idea of a required stoichiometry between
zebrafish paralogs, as the injection of native RNAs from either locus would be predicted
to skew that ratio, as would a deficiency of either paralog, This differs from injection of
human Brd2 mRNA alone, which at this same concentration, has no effect [27], suggesting
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that adding human Brd2 RNA may not disturb this ratio, as it may encode a protein that
carries both Brd2a and Brd2b activity.

Figure 8. Enhancement of morphant brain phenotypes by injection of paralogous RNA corroborates genetic antagonism between brd2a and brd2b. Rescue-Enhancement studies using zebrafish brd2a and brd2b-L in vitro-synthesized RNAs (rather than human Brd2) were used to test
functional antagonism between paralogs implied by double knockdown suppression. Panels
(A–I): Brightfield images of representative 24 hpf prim 5 embryos from indicated treatment groups.
For controls: (A) uninjected wild type, (B) brd2aRNA-injected, and (C) brd2b-LRNA-injected. For
brd2bMO rescue-enhancement: (D) brd2bMO-injected, (E) brd 2bMO + brd2b-LRNA co-injected (rescue), and (F) brd2bMO + brd2aRNA co-injection (enhancement). For brd2aMO rescue-enhancement:
(G) brd2aMO-injected, (H) brd2aMO + brd2aRNA co-injected (rescue), and (I) brd2aMO + brd2b-LRNA
co-injection (enhancement). Arrows indicate rescue (E,H) and enhancement (F,I) of morphant
brain defects by co-injection of cognate or paralogous RNA, respectively. See Table 2 for population morphology data. Panels (J–R): Darkfield images of representative 24 hpf prim 5 embryos
from the same treatment groups after TUNEL assay: (J) uninjected wildtype, (K) brd2aRNAinjected, and (L) brd2b-LRNA-injected; (M) brd2bMO-injected, (N) brd2bMO + brd2b-LRNA coinjected (rescue), and (O) brd2bMO + brd2aRNA co-injection (enhancement); (P) brd2aMO-injected,
(Q) brd2aMO + brd2aRNA co-injected (rescue), and (R) brd2aMO + brd2bRNA co-injection (enhancement). Note rescue (N,Q) and enhancement (O,R) of morphant excess apoptosis by co-injection of
cognate or paralogous RNA, respectively, supporting the idea of functional antagonism between
paralogs. See Figure 5 for quantitative TUNEL data.
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Table 2. Population morphology data: Brd2a-Brd2b rescue-enhancement studies.
Rescue Treatment a

% Defects b

2bMO rescue-2bRNA-L_brain c
control
13.0
2bMO2
40.4
2bRNA-L
39.7
brd2bMO2 + 2bRNA-L
24.6
Chi-square Contingency, Fisher’s Exact Test: p = 0.0026
Correspondence Analysis: [wildtype: control, 2bMO2+2bRNA-L] [defect: 2bMO2, 2bRNA-L]
2aMO rescue-2aRNA_brain d
Control
5
2aMO1
35
2aRNA
20
2aMO1 + 2aRNA
20
Chi-square Contingency, Fisher’s Exact Test: p = 0.1416
Correspondence Analysis: [wildtype: control, 2aMO1+2aRNA, 2aRNA] [defect: 2aMO1]
2bMO rescue-2bRNA-S_brain e
control
5
2bMO2
33.3
2bRNA-S
25
2bMO2 + 2bRNA-S
33
Chi-square Contingency, Fisher’s Exact Test: p = 0.0840
Correspondence Analysis: [wildtype: control] [defect: 2bRNA-S, 2bMO2+2bRNA-S, 2bMO2]
2bMO rescue-2bRNA-L_duct f
control
40
2bMO2
80
2bRNA-S
55
2bMO2 + 2bRNA-S
29.6
Chi-square contingency, Fisher’s Exact Test: p = 0.0128
Correspondence Analysis: [wildtype: control, 2bMO2+2bRNA-S] [defect: 2bRNA-S, 2bMO]
Enhancement Treatment g

% Defects b

2bMO enhancement-2aRNA_brainf
control
11.1
2bMO2
30.8
2aRNA
25
2bMO2 + 2aRNA
42.9
Chi-square contingency, Fisher’s Exact Test: p = 0.0059
Correspondence Analysis: [wildtype: control, 2aRNA][2bMO][defect: 2bMO2+2aRNA]
2aMO enhancement- 2bRNA-L_brain f
control
11.5
2aMO1
41.5
2bRNA-L
30.4
2aMO1 + 2bRNA-L
61.4
Chi-square contingency, Fisher’s Exact Test: p = 0.0109
Correspondence Analysis: [wildtype: control, 2bRNA-L][2aMO][defect: 2aMO1+2bRNA-L]
2aMO enhancement 2bRNA-S_braine
0
control
63.6
2aMO1
50
2bRNA-S
71.4
2aMO1 + 2bRNA-S
Chi-square contingency, Fisher’s exact test: p < 0.0001
Correspondence analysis: [wildtype: control][2bRNA-S][defect: 2aMO, 2aMO1+2bRNA-L]
2bMO enhancement-2aRNA_ductc
16.2
Control
48.2
2bMO2
50
2aRNA
69.2
2bMO2 + 2aRNA
>Chi square contingency, Fisher’s exact test: p < 0.0001
Correspondence analysis: [wildtype: control][2aRNA, 2bMO] [defect: 2bMO2+2aRNA]
a

2bMO, 4 ng; 2aMO, 4 ng; RNA, 200 pg; grey heading indicates no rescue b Only moderate severity defects were

counted for these analyses, to avoid ambiguities that may arise in scoring between wildtype and mild defects.
Bold numbers call attention to pairs directly involved in rescue or enhancement comparisons. c 50–60 embryos
per treatment d 20 embryos per treatment e 15–30 embryos per treatment f 35–50 embryos per treatment g 2bMO,
~3 ng; 2aMO, ~3ng; RNA treatments, 200 pg.
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In contrast to the brain, the morphology of the pronephric duct in embryos of brd2bMO
rescue studies shows no improvement using brd2b-LRNA co-injections, with Correspondence analysis clustering wild type with [control, 2bRNA-L] and defect with [2bMO,
2bMO + 2bRNA-L] (Table 2, 2bMO rescue 2bRNA-L_duct, p = 0.0002). Intriguingly, robust
rescue of the duct does occur when we co-inject the short transcript variant brd2b-SRNA
instead: co-injection of brd2b-SRNA reduces the incidence of defects to 29.6% compared
to 80% for brd2bMO morphants, with Correspondence analysis grouping wildtype with
[control, 2bMO+2bRNA-S] and defect with [2bRNA-S, 2bMO] (Table 2, 2bMO rescue 2bRNAS_duct, p = 0.0128). The short brd2b-SRNA transcript does not, however, rescue brd2bMO
morphant brain defects (Table 2, 2bMO rescue 2bRNA-S_brain, p = 0.0840), suggesting that
brd2b-SRNA has specific functions in the developing pronephros but is less critical for
normal brain formation.
Once we verified that zebrafish Brd2 RNAs from each locus could rescue their respective MO knockdown phenotypes, we used these same RNAs in corresponding genetic enhancement studies (see Materials and Methods). Treatment groups for brd2bMO
enhancement (control uninjected, brd2bMO2, brd2aRNA, and brd2bMO2 + brd2aRNA coinjection) and for brd2aMO enhancement (control uninjected, brd2aMO1, brd2b-LRNA,
and brd2aMO1 + brd2b-LRNA co-injection), were assessed for brain and trunk morphology.
Representative brain images from these experiments are shown in Figure 8 and quantitative population data are presented in Table 2. brd2bMO morphant brain defects are
often enhanced by co-injection of paralogous brd2aRNA (Figure 8D vs. Figure 8F), with
a smaller brain and a more triangular-shaped MBH region (arrow in Figure 8F). Similarly, brd2aMO morphant brain defects are often enhanced by co-injection of paralogous
brd2bRNA-L (Figure 8G vs. Figure 8I), with further loss of brain segment definition (arrow
in Figure 8I). Quantitative analysis of population data support these brain enhancement
observations in terms of penetrance: brd2bMO moderate brain defects increase in incidence from 30.8 to 42.9%, and brd2aMO brain defects increase from 41.5 to 61.4%, with
co-injection of their respective full-length paralogous RNAs (Table 2, 2bMO enhancement
2aRNA_brain, p = 0.0059; 2aMO enhancement 2bRNA-L_ brain, p = 0.0109). In addition, Correspondence analysis groups wild type with [control], and moderate defect most closely
with [2bMO + 2aRNA], in each case. In contrast, the short transcript, brd2b-S, does not
enhance the brd2aMO brain defect (Table 2, 2aMO enhancement-2b-S_brain, p < 0.0001), with
Correspondence analysis grouping defect closely with both [2aMO, 2aMO+2bRNA-S] As
for the pronephros, co-injection of brd2aRNA enhances the brd2bMO morphant phenotype
in the duct also, increasing the incidence of defects over that seen with either reagent alone
(Table 2, 2bMO enhancement 2aRNA_duct, p < 0.0001). Correspondence analysis groups wild
type with [control] followed by [2aRNA, 2bMO1], with defect most closely associated with
[2bMO1 + 2aRNA]. Thus, levels of both brd2b-S RNA (as seen in rescue above) and brd2a
RNA (as seen in enhancement here) may be involved in negotiating normal pronephric
duct development. Taken together, these studies confirm that enhancement with increased
penetrance of brd2aMO and brd2bMO morphant brain and duct phenotypes is obtained by
co-injection of the paralogous full-length RNA, which presumably would further skew the
Brd2a/Brd2b ratio.
To corroborate our morphological observations, we extended genetic rescue-enhancement
studies to assess differential cell death levels in prim 5 individuals across treatment groups
using TUNEL assays. Although the previous rescue-enhancement treatments could be
evaluated in terms both of penetrance and expressivity of brain defects, this was less true
with respect to the pronephric duct, where we saw penetrance differences but were unable
to parse out severity levels. Consequently, we focused on brain samples for quantitative studies of differential cell death levels that might underlie morphologies observed.
Treatment groups for cell death rescue-enhancement studies were the same as for morphological experiments. Representative samples for each treatment are shown in Figure 8J–R;
quantitative population data are shown in Figure 5E–H. Consistent with morphological
observations, elevated levels of cell death in morphants were partly rescued by co-injection
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of RNA from the corresponding locus (Figure 8M vs. Figure 8N; Figure 8P vs. Figure 8Q).
Quantitative population data support these observations: brd2bMO morphant brains displayed, on average, 534.67 apoptotic nuclei compared to 367.33 in embryos co-injected
with cognate brd2b-LRNA (Figure 5E, p = 0.0286); furthermore, brd2aMO morphant brains
showed, on average, 848.0 apoptotic nuclei compared to 562.7 in embryos co-injected
with cognate brd2aRNA (Figure 5G, p = 0.0176). Conversely, co-injection with the RNA
of the paralogous locus exacerbated the excess cell death in morphants (Figure 8M vs.
Figure 8O; Figure 8P vs. Figure 8R). Quantitative population data are consistent with
these observations: brd2bMO morphants displayed, on average, 457.0 apoptotic nuclei
compared to 806.0 in embryos co-injected with paralogous brd2aRNA (Figure 5F, p = 0.0008);
similarly, brd2aMO morphants showed an increase from 743.7 to 1167.0 apoptotic nuclei
in embryos co-injected with paralogous brd2b-LRNA (Figure 5H, p = 0.0084). As noted
in morphological studies, injection of either brd2aRNA or brd2b-LRNA alone results in
a mild phenocopy, with cell death levels elevated above wild type, but not as high as
in MO-treated morphants (Figure 8J vs. Figure 8K,L; Figure 5E–H, compare none and
RNA alone injections in each case), again supporting the idea of a required stoichiometry
between paralogs. Taken together, these results suggest that paralogs brd2b and brd2a
interact genetically as functional antagonists during zebrafish development to effect proper
formation of the brain, in part through their co-regulation of cell death.
4. Discussion
Our comparative studies of zebrafish brd2a and brd2b reveal both shared and unique
structural, regulatory, and functional features in the two paralogs, and provide a concrete
example of how gene duplication and divergence might contribute to the evolution of gene
networks and developmental pathways. In the case of zebrafish Brd2, diversification is
exemplified through paralog-specific RNA variants and protein isoforms, distinct localization of maternal factors, shared and unique tissue- and stage-specific expression and
function, and novel genetic interactions.
4.1. Shared and Distinct Functions of Brd2b/2a Paralogs
4.1.1. RNA Variants and Protein Isoforms
Both Brd2 paralogs exhibit RNA variants encoding putative protein isoforms lacking
one or more of the canonical BET domains. We show that long and short brd2b transcript
variants are distinctly regulated: whereas brd2b-L RNA is a maternal-zygotic transcript
expressed in both oocytes and embryos, brd2b-S is a zygotic transcript expressed specifically in segmentation stage and older embryos. The short transcript encodes a predicted
protein that carries only bromodomain 1 (BD1); this might function as a dominant-negative
factor by binding target loci of full-length Brd2b or Brd2a but failing to bring associated
protein cargo. This idea is supported by recent studies showing the ET domain to be crucial
for Brd2 association with chromatin and for its transcriptional and splicing effects [49].
Alternatively, or in addition, Brd2b-S protein (or the brd2b-S RNA itself) could have its own
unique co-transcriptional or other activity. In any case, the short brd2b variant/isoform
specifically is critical to proper formation of the pronephric duct, consistent with its zygotic expression during segmentation. A third predicted brd2b transcript variant that is
listed in the Ensemble database (GRCz11 release) but is as-yet unsupported by cDNA
evidence, encodes a different truncated protein containing a partial BD2, an NLS and
ET domain (brd2b-201 from ENSDARG_00000046087). Similarly, paralog brd2a produces
two verified transcript variants encoding nearly identical full-length BET proteins [27]
(NCBI NM_001270571.1, NM_131200.2), and two predicted transcripts encoding truncated
proteins—one containing BD1 and partial BD2 alone (NCBI XM_021467982.1), and another,
a partial BD1 alone (Ensemble, GRCz11 release, brd2a-202 from ENSDARG_00000022280),
respectively. Thus, transcript variants and protein isoforms with different subsets of BET
domains may be characteristic of Brd2 paralogs in zebrafish, and possibly, of Brd2 and other
BET genes in other species. In fact, according to the NCBI Gene database, the human Brd2
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locus produces up to five RNA variants resulting in four predicted protein isoforms, one of
which lacks the majority of BD1 (NP_001278915.1). Other potential isoforms lacking the
ET domain or containing only BD1 (as in Brd2b-S here) are listed in Ensemble (GRCh38;
ENSG00000204256.14). Interestingly, both databases also list non-coding RNAs or RNAs
with retained introns for human Brd2. Long and short transcripts from alternate promoters,
and alternatively spliced transcripts retaining part of a conserved intron carrying a premature stop codon (such as brd2b-S), were previously observed for mammalian Brd2 [50];
intriguingly, the ratio of regular to alternative splice variants is regulated by the length of a
polymorphic repeat nearby, implying stoichiometry among variants is key [50]. Finally, in
flies, zebrafish, mice and humans, Brd2 RNA variants and/or protein isoforms may be preferentially expressed in distinct tissues or stages [4,27,50,51]. Together, these observations
suggest complex modularity among Brd2 isoforms, and possibly combinatorial regulatory
outcomes from their division of labor and/or interactions.
4.1.2. Maternal-Zygotic Function
All known Brd2 species homologs, as well as both Brd2 paralogs in zebrafish, encode
maternal and zygotic factors, implying conserved function in germline and early developmental events [23–25]. However, while zygotic factors from the two zebrafish paralogs
overlap greatly in spatial expression in embryos, maternal factors localize to strikingly
different regions in stage IV oocytes—Brd2a in the peripheral cortical cytoplasm and Brd2b
restricted to the future animal pole ([25,27], and this study). This suggests functional
divergence between paralogs, perhaps in epigenetic reprogramming events at the earliest
stages of development. In fact, epigenomic studies reveal unique chromatin landscapes
in oocytes, sperm, and early embryos, including differences in chromosome organization
and accessibility [52]. Significantly, the epigenetics and 3D architectures of the genome
undergo dramatic changes at developmental transitions such as those associated with
egg maturation, meiotic reentry, the egg-to-embryo transition, and activation of zygotic
transcription [53]. Presumably, this leads to selective access to chromatin and correct
deployment of gene regulatory programs. By localizing to distinct regions within oocytes,
zebrafish Brd2 paralogs may access different gene sets or organize chromosome topologies
in different areas of the genome, in preparation for embryogenesis. Recently, BET proteins
have been directly implicated in higher order chromatin structure and chromosome organization as well as in regulation of developmental transcriptional programs. For example,
testis-specific BRDT regulates chromatin organization and epigenetic reprogramming during prophase I of male mammalian gametes and is necessary for the defined topology of
the chromocenter in post-meiotic spermatids [8]. In embryonic stem cells (ESCs), Brd2 acts
as an antagonist of histone 2A.Z (H2A.Z) at promoters of poised, bivalent genes, maintaining a balance between activation and repression of chromatin that is critical to proper
execution of developmental programs [54]. Finally, and more generally, Brd2 co-localizes
with chromatin insulator protein CTCF genome-wide to effect transcriptional boundaries
between sets of genes, a “bookmarking” activity that potentiates gene co-regulation [55].
The zygotic activities of both Brd2 paralogs center on the formation and patterning of segmented or compartmentalized tissues including the brain, spinal interneurons,
PBI, and pronephric duct, echoing ancient Hox-dependent segmentation functions from
Drosophila [4,23]. Indeed, the fly homolog of Brd2, fs(1)h, encodes long and short isoforms,
and exhibits maternal and zygotic mutant alleles that affect different BET domains and
cause distinct segmentation and homeotic defects. For instance, maternal alleles carrying a deletion of the ET domain of the long isoform lead to segmentation defects via
homeobox gene engrailed (eng) misexpression and trunk homeosis via the homeobox gene
Ultrabithorax (Ubx), whereas a mutation in BD-1 in this same isoform leads to termini
deletions via RAS signaling [26]. In contrast, a zygotic allele carrying a BD-1 mutation in
the short isoform leads to head homeosis via misexpression of homeobox genes Deformed
(Dfd) and labial (lab), and to gut defects via cap’n’collar (cnc) [26]. Interestingly, another
zygotic temperature-sensitive allele of fsh-S results in reduced Ubx expression in the VNC of
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Drosophila embryos [4], suggesting that a Brd2/Hox pathway might be involved in VNCderived interneuron mispairing seen in both zebrafish brd2a and brd2b morphants [25,27].
Recent work has uncovered a role for Hox genes in morphogenesis and lineage fidelity in
developing mammalian kidney, suggesting that pronephric abnormalities seen in brd2a and
brd2b morphants may also involve misregulation of homeobox genes [56]. Thus, modularity,
temporal-spatial specificity of isoforms, distinct maternal and zygotic functions, and intersection with Hox-dependent patterning pathways, are ancient features of Brd2 that appear
to be retained across species and in both zebrafish paralogs. Zebrafish paralogs appear
to diverge, however, in some downstream patterning genes in the brain such as eng2a,
krox20, and pax2a, where only brd2a deficiency results in expression defects [27]. Thus, Brd2
paralogs may act in both shared and distinct processes during CNS development, perhaps
displaying redundancy or sub-specialization depending on context.
4.1.3. Cell Death, Differentiation, and Lineage Specification
Both Brd2 paralogs affect the developing CNS, PBI, and pronephric duct in large part
by suppressing cell death during stages when differentiation, patterning, morphogenesis,
and lineage specification are ongoing. In the CNS, the deficiency of either paralog results
in nearly identical defects: high levels of neuronal apoptosis leading to reduced hindbrain,
an ill-defined MHB region, and a deformed spinal cord. There is growing evidence of
the importance of Brd2 across species in the control of neuronal apoptosis, differentiation,
and/or proliferation. Similar in many ways to zebrafish knockdowns, Brd2 knockout
mice exhibit excess apoptosis, reduced brain, neurulation defects, hindbrain exencephaly
and transcriptome changes in neurogenesis genes, prior to embryonic lethality [31,32].
Other studies show Brd2 is necessary for the cell cycle exit and neuronal differentiation of
mouse neuroepithelial cells, as a deficiency of Brd2 increases proliferation and decreases
neuronal differentiation [36]. Significantly, this phenotype is suppressed in Brd2/E2F
double mutants, implying an antagonistic relation between Brd2 and cell cycle promoter
E2F in this neuronal context. Finally, in a Brd2 (+/−) haploinsufficient mouse model of
juvenile monoclonal epilepsy (JME), the number of GABAergic neurons is reduced in
the striatum and primary motor cortex, suggesting that Brd2-dependent neurogenesis is
critical for the proper differentiation of specific neuronal cell types [38]. A connection
between Brd2 and neuronal differentiation is also seen in Drosophila, as a zygotic loss of
function (LOF) allele of fsh-S results in loss of terminal dendritic branches and impaired
mechanosensory responses [57]. Together, these observations suggest that the involvement
of Brd2 in neuronal development is ancient and evolutionarily conserved, although a more
recent role for Brd2, specifically in neuronal apoptosis, only, as far as we know, appears in
vertebrates, and is retained in both zebrafish paralogs.
Both zebrafish Brd2 paralogs are likely involved in the formation of blood and
pronephric (kidney) tissues, but display some unique, even opposing, phenotypes when
deficient. Given that blood and kidney precursors arise from a common progenitor field in
the intermediate mesoderm [46], paralog activity might affect lineage specification and/or
concurrent processes of mitosis, apoptosis, and cellular differentiation. The deficiency of
either paralog results in an unstructured and sparsely populated PBI, likely due in part to
the increased apoptosis in the region. However, the penetrance of this defect differs greatly
between paralogs, implicating brd2a as the prevailing regulator in PBI tissue. In contrast,
the two paralogs appear to act in opposite directions when it comes to the pronephric duct:
whereas knockdown of brd2a results in a dramatic increase, knockdown of brd2b shows
a significant decrease, of Pax2a(+) pronephric cells along the ductal tube. Misregulation
of apoptosis is unlikely to account for either an excess or deficit of ductal tube cells, as
levels of cell death and numbers of cells in this region do not co-vary in the expected
directions in either Brd2MO morphant. This leads us to believe that differential mitosis or
differentiation and/or a switch in cell fate specification may be involved. Brd2a deficient
embryos may display an increase in kidney precursors at the expense of blood precursors,
for instance [47], which would be consistent with the known requirement of Brd2 for proper
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hematopoiesis in mammals [13,30] and zebrafish [29]. A careful examination of knockdown effects in this region using cell-type-specific markers for blood and kidney lineages
would help elucidate mechanisms at play. Misregulation of apoptosis is likely involved
specifically at the cloaca, however, as lack of apoptosis in brd2bMO morphants correlates
with excess cells plugging the opening. It is also possible that a change in distribution or
migration of Pax2a(+) cells to the distal tip accounts for the cloacal defect in brd2bMO
morphants, as we see an increase in cells at the cloaca with a concomitant decrease in cells
along the tube. Taken together, these findings suggest that, normally, brd2a may promote
the formation of blood precursors, while brd2b aids in the proper formation/distribution
of kidney precursors, and furthermore, that paralogs work together to achieve a normal
PBI and duct, possibly through their combined regulation of cell death, mitosis, and/or
(possibly Hox-dependent) differentiation during lineage specification in the ventral trunk.
More generally, the two paralogs appear capable of exerting opposite phenotypic outcomes,
depending on context and tissue.
Corroborating these findings, work using genetics and small molecule BET inhibitors provide
evidence for the involvement of Brd2 and/or other BET proteins in hematopoiesis [13,29,30], erythroid specification and transcriptome activation [13], hematological malignancies [17,18,30,34],
and the modulation of pathways relevant to chronic kidney disease [19]. In addition, BET
proteins are implicated as regulators of cell state transitions and cellular identity in various
models [10–14]. Significantly, basic helix-loop-helix (bHLH) transcription factors mediate
the epigenetic response elicited by the treatment of some cancer cells with BET inhibitors,
implying that BET proteins connect specifically with transcriptional networks of bHLHinfluenced developmental pathways—namely, those that critically regulate neurogenesis,
cell proliferation and differentiation, and cell lineage determination [58]. Finally, lineagespecific transcription factors are known to recruit BET proteins to specific chromatin sites in
response to cellular signals, inducing transcriptional programs and stabilizing desired cell
states. For example, recruitment of Brd2 by transcription factor Lyar helps reduce levels of
pro-proliferative Nanog upon differentiation signaling; deletion of the Brd2-binding site
of Lyar leads to impaired differentiation and increased cell death [59]. In another context,
an isoform switch between Brd2 and Brd4 occupancy at Nodal-regulatory elements (NRE)
dictates whether cells retain the pluripotent state or take on a lineage-specific fate [60].
Brd2 is also involved in mediating fate switching in osteoclast [61] and erythroid [62]
lineages, and in the epithelial to mesenchymal transition (EMT) [63], where it acts antagonistically with Brd3/4. Possibly, a similar switching mechanism between Brd2a and Brd2b
paralogs creates the proper balance of Pax2a(+) kidney vs. Pax2a(−) blood precursors from
a common progenitor field.
4.2. Functional Antagonism between Brd2 Paralogs
We provide evidence for genetic interaction with functional antagonism between
brd2a and brd2b, showing that double knockdown suppresses the morphant defects we
observe when either paralog is knocked down individually. Strikingly, double knockdown
suppression rescues defects whether they are similar or opposite in effect in each single
knockdown, or in fact, unique to a single knockdown. Thus, antagonism between paralogs
may work in multiple contexts and via shared and individual regulatory pathways. We
provide support for the idea that a proper ratio between the two paralogs must exist at
some level for normal development to occur, by further skewing that presumed ratio
with co-injection of paralogous RNA, and thereby enhancing single knockdown defects.
Whether the balance of gene products is achieved through direct or indirect interaction
between paralogs is yet unknown. Both homodimers and heterodimers can form among
BET family members [1,48], so direct interaction is plausible; indeed, a conserved motif B in
bromodomains provides a surface for homo- and hetero-dimerization, and is necessary for
association with chromatin [48]. In any case, a skewed 2a:2b ratio presumably could alter
the concentration-dependent regulation of specific developmental pathways, leading to, for
instance, excess cell death in the CNS or a switch in cell fate in the ventral trunk, ultimately
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explaining the defects we observe. A summary of our findings and a potential model for
interaction with functional antagonism between paralogs, assuming direct hetero- and
homodimer formation, is presented in Table 3, and may be referred to in the discussion
below.
Table 3. Summary of paralog interaction with functional antagonism.
Morphant Defects

CNS
Brain Morphology/PCD
MHB Genes
VNC Interneurons
PBI
Morphology/PCD
Pronephric Duct
Tube PAX2a(+)
Cloaca
Plug
PCD
PAX2a (+)
Circ/Lethality

a

Brd2a Deficiency
2AMO

2BRNA-L

X
X
X

X

Brd2b Deficiency
2BRNA-S

2ARNA

2AMO + 2BMO

X
WT
X

X

WT
WT
WT

X

X

X (+)

X (−)

WT
WT
WT

Xb

Suppression

2BMO

X
X (−)
X (+)
X

WT

Path a

Skew from WT
AA:AB:BB

AA:AB:BB

AA < AB < BB or AA > AB > BB
AA < AB < BB
AA < AB < BB or AA > AB > BB
AA < AB < BB or AA > AB > BB
AA < AB < BB

X

WT
WT
WT
WT

pcd+
hox
hox
pcd+

AA > AB > BB

lin+ m
lin− m

AA > AB > BB b
AA > AB > BB
AA > AB > BB
AA > AB > BB

pcd+ m
pcd−
pcd− m
???

potential pathway involved: pcd = cell death; hox = homeobox; lin=lineage specification; m = mitosis or migration.
brd2b-s rna short variant; red “B” indicates Brd2b-S protein short isoform.

b

red X indicates

Our study of brd2a and brd2b paralogs in different tissues suggests a variety of possible
mechanisms for functional antagonism. In the brain, a deficiency in either Brd2a or Brd2b
results in the same defects of excess apoptosis and dysmorphology, implying similar
action, occurring perhaps in a shared pathway. These defects are suppressed by double
knockdown, enhanced by co-injection of each morpholino with the paralogous RNA,
and phenocopied by injection of the respective paralogous RNA alone. This suggests a
functional antagonism based on a proper balance of 2a:2b, where skewing in either direction
results in pathway misregulation and ectopic cell death (Table 3, CNS). Alternatively, the
paralogs may participate in separate pathways that intersect at some point down the line.
Enhancement and phenocopying of brd2aMO occur specifically with brdb2-L rather than
brd2b-S RNA injections, implicating full-length Brd2b-L as co-regulator with Brd2a of
apoptosis in the developing CNS.
In the ventral trunk, the morphogenesis of the PBI and pronephric duct is affected by
deficiencies in either paralog, but in diverse ways. As in the brain, a deficiency in either
paralog results in excess cell death in the PBI, and this defect is substantially suppressed by
double knockdown. Thus again, a balance between the two paralogs may be required for
normal PBI formation, and a relative deficit of one or the other leads to excess apoptosis in
this region (Table 3, PBI). The PBI is considered a transitional hematopoietic tissue where
erythromyeloid progenitors (EMPs) mature into erythroid and myeloid cells from 19 to
24 hpf [43]. As these various cell types coexist in the PBI at the time of our assay (24 hpf), it
is possible that the paralogs act in different lineages, with some crosstalk between them to
allow for double knockdown suppression.
As mentioned already, Brd2 paralogs exhibit opposite morphant defects in the developing pronephric duct: while Brd2a deficiency results in an excess of Pax2a(+) pronephric
cells along the ductal tube, a deficiency of Brd2b results in fewer such cells. These single knockdown defects are partially suppressed in the double knockdown, such that the
cell density and distribution are closer to wildtype. As both pronephric and blood cells
normally reside in this region of the ventral trunk, several mechanisms of antagonism
are possible in which Brd2a promotes blood cell fate, proliferation and/or survival, while
Brd2b does the same in pronephric cells. Thus, in the ductal tube region, the 2a:2b ratio
might function as a concentration-dependent switch, where skewing in either direction
upsets a balance between alternate developmental programs and/or fates in blood and
kidney cells (Table 3, Pronephric duct). A unique situation occurs at the distal tip of the
pronephric duct, where a deficiency of Brd2b—but not of Brd2a—results in a plug of
excess Pax2a(+) cells at the cloaca with concomitant reduced apoptosis. Cloacal defects are
substantially suppressed in the double knockdown, enhanced by co-injection of paralogous
brd2a RNA, and phenocopied by ectopic injection of paralogous brd2a RNA alone. This
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suggests an antagonistic ratio that is allowed to skew in only one direction: levels of Brd2b
must surpass a minimum threshold, while levels of Brd2a must fall below maximum threshold (Table 3, Cloaca). Reduced Brd2b might still be compensated by reduced antagonist
Brd2a in the double knockdown. Significantly, cloacal occlusion is rescued selectively
by brd2b-S rather than brd2b-L RNA; so the truncated Brd2b-S isoform, and presumably,
the Brd2b-S:Brd2a ratio, appear important for proper formation of this structure. The
onset of expression of brd2b-S RNA by early segmentation and its perdurance until at least
48 hpf correlates with the timing of pronephric duct morphogenesis, and is consistent
with these data. Intriguingly, brd2a transcripts appear transiently degraded in vivo during
mid-segmentation in wildtype when brd2b-S is most prominent [27], skewing the ratio in
the proposed “permitted” direction. A complicating factor is that injection of brd2b-S RNA
alone also phenocopies the brd2bMO defect at the cloaca—this might indicate a ceiling to
brd2b-S expression, above which interactions with other targets may occur that interfere
with the normal course of events at the cloaca. The fact that Brd2b-S is missing the ET
domain and may act as a dominant negative, might allow it to repress BET proteins other
than Brd2a, for instance.
Taken together, these studies show that Brd2 paralogs in zebrafish have developed
novel interactions that work in concentration-dependent and antagonistic ways to modulate
shared, one-sided, and/or alternate developmental pathways in different tissues and
developmental contexts.
4.3. Gene Duplication, Divergence, and Antagonism
Numerous studies describe paralogous genes that have developed interactions and/or
antagonistic relationships of various kinds, highlighting the evolutionary significance of
such events, and providing precedent and context for our findings. First, BET proteins
are known to interact to effect different regulatory outcomes. For example, Brd2 and
Brd4 co-occupy superenhancer elements to regulate the inflammatory response [6], and
both cooperate with Myc at shared sites to promote osteoclast over macrophage cell
fate [61]. In addition, Brd2, 3, and 4 are recruited to GATA-regulated genes, in a preferred
stoichiometry, to activate erythroid transcription; in this context, ectopic Brd3 rescues
Brd2, but not Brd4, deficiency, implying both distinct and redundant BET functions [62].
On the other hand, Brd2 and Brd3/4 activate independent transcriptional networks and
thereby compete with one another to promote or repress, respectively, the epithelial to
mesenchymal transition (EMT) in a breast cancer model [63]. Thus, BET proteins interact
both cooperatively and antagonistically, and in both indirect genetic and direct biochemical
fashion. Second, other more recently diverged paralogs are known to interact in ways
that resemble what we see with zebrafish Brd2. For instance, antagonistic paralogs can
affect a single pathway in opposite direction, as do Ubf3a and 3b in the nonsense-mediated
decay (NMD) pathway [64]. Here, repressor paralog Upf3a lacks a critical domain and
acts as a dominant negative “rheostat” on active paralog Upf3b by competitive blocking.
Dominant-negative mechanisms are considered common in gene evolution [64] and may
be applicable in our case to Brd2-S. Antagonistic paralogs can also act as ON/OFF switches
of a single pathway by having opposite transcriptional effects on the same set of target
genes, as pals-22 and pals-25 do in the intracellular pathogen response (IPR) pathway
of C. elegans [65]. On the other hand, paralogs can control different unique pathways
by their concentration-dependent effects on a common molecular target. For example,
paralogs antagonistically controlling epigenetic co-regulator lysine demethylase 1 (LSD1) during hematopoiesis, either promote megakaryocyte cell fate or lead to erythroid
differentiation from a common precursor, depending on their relative concentrations [66].
Something along these lines might characterize the action of zebrafish Brd2 paralogs in
blood versus pronephric lineages. Finally, paralogs often exhibit sub-functionalization after
duplication, presumably allowing division of labor and complementary interactions [67].
We believe this likely occurred here, as the single human Brd2 RNA rescues morphant
defects of either zebrafish paralog, while zebrafish RNA from each paralogous locus
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rescues only its own morphant defects. In addition, brd2a and brd2b exhibit at least some
unique spatiotemporal expression patterns, both in oocytes and embryos [25], suggesting
functions that may be completely independent and the result of either sub-functionalization
or neofunctionalization. It is also possible, however, that Brd2b is simply a repressor of
Brd2a, and has no other independent function of its own. In this case, the levels of Brd2a
would be all that matter, causing defects when either too high or too low, depending
on context. We believe this might be true of truncated Brd2b-S, but less likely for fulllength Brd2b-L, given the history of BET protein interse interactions. Finding a defect
unique to one paralog that is not suppressed by the deficiency of the other paralog, and/or
attempting rescue of nulls of either paralog with ectopic expression of the other, might help
to definitively resolve this issue.
5. Conclusions
In summary, our study of zebrafish Brd2 paralogs provides a concrete example of
divergence after gene duplication that illustrates multiple levels of diversification, including the following: paralog-specific variants/isoforms and domain configuration changes;
both shared and unique spatiotemporal expression and function; both shared and possibly
unique developmental pathways; and concentration-dependent genetic interaction with
functional antagonism. It will be of future interest to assess paralogs for direct biochemical
interaction, to identify their shared and unique upstream regulators and downstream
targets, and to compare transcriptome changes brought about by single and double knockdowns. Diversification of paralogs has allowed for increased complexity of regulatory
networks, more crosstalk between networks controlling different processes, and greater
selectivity and specificity of signaling pathways [68]. Thus, studies such as these deepen
our understanding of a major mechanism of evolution and development. Just as importantly, the study of Brd2 paralogs in zebrafish may provide novel insights into possible
functions, activities, and interactions of human Brd2, which as a member of the BET family
of epigenetic co-regulators, stands at the intersection of multiple regulatory pathways,
including those involved in carcinogenesis and neurodegeneration. Master regulatory proteins such as Brd2 are likely to belong to “critical paralog groups”—the subset of paralogs
that are more central to signaling pathways, more varied in biological function and complex in post-transcriptional regulation, and more likely to be mutated in genetic diseases
and cancer [69]. Their investigation presents a unique opportunity for understanding the
mechanisms of control circuits critical for development and normal biological function, as
well as their evolution and complexification over time.
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